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Pyrazinamide (PZA) is one of the drugs included in the standardized TB treatment regimen for both 
drug susceptible and resistant TB. PZA has a unique ability to target persister bacilli and since its 
inclusion has reduced TB treatment duration to 6 months. However, drug susceptible testing (DST) 
for PZA is not routinely performed due to the challenges associated with the DST (acidic media; false 
resistance and inoculum size). Significant evidence indicates that mutations in pncA (gene encodes for 
pyrazinamidase (PZase)) are the primary mechanism of resistance to PZA. Sequencing studies reveal 
that mutations occur across the entire length of the gene, thus sequencing of the entire gene is required 
to capture all possible resistance conferring mutations. A rapid molecular diagnostic is required to 
routinely test for PZA resistance, especially given the continued recommendation of its inclusion in 
the shortened MTB treatment regimen.  
PZA is currently being considered for inclusion of new treatment regimens which also include the 
newer anti-TB drugs. However, we need to better understand the prevalence of PZA resistance 
globally and across the spectrum of drug resistant groups to determine the utility of this drug in 
current and future treatment regimens. This PhD thesis aims to further the current knowledge of PZA 
resistance.  
The prevalence of PZA resistance regionally and globally is largely unknown. Our systematic review 
collates the PZA resistance data in the literature from all TB cases (16.2%); in high-risk MDR-TB 
(41.3%) and in MDR-TB (60.5%). These findings caution against relying on PZA in current and 
future TB drug regimens, especially in MDR-TB patients. This review also identified more than 600 
unique SNPs across the entire length of the pncA gene as the causal mechanism of resistance. This 
highlights the complexity of the challenge to develop future genetic based PZA resistance tests. 
From this review it was evident that the prevalence of PZA resistance across a spectrum of drug 
resistant isolates is unknown. To address this knowledge gap 775 clinical isolates from South Africa 
were classified into groups according to resistance profile (ranging from pan-susceptible to XDR-TB) 
and their association with PZA resistance was determined. The prevalence of PZA resistance in each 
group was: 0% in the pan-susceptible; 2% in the INH-mono; 7.5% in the RIF-mono; 39.3% in the 
MDR-TB and 96.8% in the XDR-TB group. A statistically significant increase in PZA resistance was 
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observed as the number of resistance markers increases. We concluded that PZA DST should be 
performed when considering its inclusion in treatment of patients with rifampicin-resistant TB or 
MDR-TB. This study also showed an excellent correlation between pncA genotype and PZA 
phenotype. The resulting sensitivity and specificity was 95% and 99%, respectively, thereby 
confirming the utility of pncA sequencing as a rapid PZA susceptibility test. 
In an attempt to understanding discordance between genotype and phenotype we characterised pncA 
mutations which did not confer PZA resistance at a susceptibility breakpoint of 100 µg/ml 
pyrazinamide in MGIT. A total of 10 non-resistance conferring mutations were identified in 
collaboration with the U.S. Centers for Disease Control and Prevention. These results will be essential 
for the interpretation of pncA sequencing results to guide treatment. 
In a recent paper the authors suggested that pncA mutation have a fitness cost which would impact on 
the transmission of drug resistant M. tuberculosis strains. To test this hypothesis we compared the 
growth rates of clinical isolates and in vitro mutants (wild type and SNPs) and clinical isolates which 
have a large pncA deletion. No difference was observed in the time to positivity in MGIT media when 
comparing wild type and strains harbouring pncA mutations, thereby suggesting that pncA mutation 
do not have a significant fitness cost. However, strains harbouring large pncA mutations showed a 
significant growth deficit (p-value: <0.001) in vitro. However, this fitness cost did not prevent these 
strains from transmitting in the community.   
In an attempt to simplify the diagnosis of PZA susceptibility, we investigated the diagnostic utility of 
a LATE-PCR based technique in combination with fluorescence probes to identify mutations along 
the entire length of the pncA gene. Using this method the sensitivity and specificity was 98.7% and 
98.4%, respective, suggesting that this method could be using in routine laboratories due to the single 
tube format.  
Together this body of research has addressed critical knowledge gaps and has introduced a 
methodology that could simplify the diagnosis of PZA resistance. 




Pyrazinamide (PZA) is ‘n middel wat gebruik word in die standaard behandeling van beide sensitiewe 
en weerstandige tuberkulose (TB). PZA beskik oor die unieke vermoë om langlewende bakterieë te 
teiken en het sedert die insluiting daarvan in die behandelingsregime die duur van TB behandeling 
verminder tot 6 maande. Middel weerstandige toetsing (MWT) vir PZA word selde uitgevoer as 
gevolg van uitdagings wat geassosieer word met MWT (suur media, vals positiewe weerstandigheid 
en inokulum grootte). Betekenisvolle resultate het gewys dat mutasies in pncA (die geen wat kodeer 
vir pyrazinamidase (PZase)) die primêre meganisme is wat lei tot PZA weerstandigheid. 
Volgordebepaling het gewys dat mutasies oor die hele lengte van die geen voorkom en gevolglik  
moet die hele geen se volgorde bepaal word om al die moontlike mutasies wat kan bydra tot 
weerstandigheid te identifiseer. ‘n Vinnige molekulêre diagnostiese toets word benodig om op ‘n 
gereelde basis te kan toets vir PZA weerstandigheid, veral gegewe die volgehoue aanbeveling dat 
PZA ingesluit moet word in die verkorte TB behandeling.   
PZA word tans oorweeg vir die insluiting in nuwe behandelingsregime wat ook nuwer anti-TB 
middels sal insluit. Ons benodig egter verbeterde kennis omtrent die globale voorkoms van PZA 
weerstandigheid oor die spektrum van weerstandige groepe om vas te stel wat die verbruik van die 
middel in die huidige en toekomstige behandeling is. Die doel van hierdie PhD tesis is om die huidige 
kennis van PZA weerstandigheid uit te brei.  
Die plaaslike en globale voorkoms van PZA weerstandigheid is grotendeels onbekend. Ons 
sistematiese oorsig artikel vat die beskikbare PZA weerstandige data in die literatuur oor alle TB 
gevalle (16.2%), in hoë risiko multiweerstandige TB (MDR-TB) (41.3%) en in MDR-TB (60.5%) 
gevalle saam. Hierdie bevindinge waarsku teen die betroubaarheid van PZA in huidige en 
toekomstige TB behandeling, veral in MDR-TB pasiënte. Die studie het meer as 600 unieke 
enkelnukleotied polimorfismes oor die lengte van die pncA gene geïdentifiseer as die oorsaak van 
weerstandigheid. Dit beklemtoon die kompleksiteit van die uitdaging om toekomstige geneties 
gebaseerde PZA weerstandige toetse te ontwikkel.  
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Hierdie oorsig artikel het ook daarop gedui dat die voorkoms van PZA weerstandigheid oor ‘n 
spektrum van middel weerstandige isolate onbekend is. Om hierdie gebrek in kennis aan te spreek is 
775 kliniese isolate van Suid-Afrika geklassifiseer in groepe volgens hul weerstandige profiele (wat 
strek van middel vatbare to XDR-TB) en is hul assosiasie met PZA weerstandigheid bepaal. Die 
voorkoms van PZA weerstandigheid in elke groep was soos volg: 0% in die middel vatbare; 2% in die 
INH-enkelweerstandig; 7.5% in die RIF-enkelweerstandig; 39.3% in die MDR-TB en 96.8% in die 
XDR-TB groep. Soos die aantal weerstandige merkers toeneem is ‘n beduidende verhoging in PZA 
weerstandigheid waargeneem. Ons het beveel aan dat PZA MWT uitgevoer moet word wanneer dit 
oorweeg word om pasiënte met rifampisien-weerstandige TB of MDR-TB ook met die middel PZA te 
behandel.  Hierdie studie dui ‘n uitstekende korrelasie tussen pncA genotipes en PZA fenotipes aan. 
Die sensitiwiteit en spesifisiteit was onderskeidelik 95% en 99%, wat die bruikbaarheid van pncA 
volgordebepaling bevestig as ‘n vinnige PZA sensitiewe toets.  
In ‘n poging om die teenstrydigheid tussen genotipe en fenotipe te verstaan, het ons pncA mutasies 
wat nie PZA weerstandigheid veroorsaak by ŉ konsentrasie van 100 µg/ml nie, in meer diepte 
ondersoek. ‘n Totaal van 10 mutasies wat nie bydra tot weerstandigheid nie is geidentifiseer in 
samewerking met die VSA se Sentrum vir Gesondheidsbeheer en Voorkoming. Laasgenoemde data is 
krities vir die interpretasie van pncA volgordebepaling resultate om behandeling voor te kan skryf.  
In ‘n onlangse artikel het die outeurs voorgestel dat die fiksheid koste van pncA mutasies ‘n impak het 
op die oordrag van middel weerstandige M. tuberculosis stamme. Om hierdie hipotese te toets het ons 
die groei tempo van kliniese isolate en in vitro mutasies (wilde tipe en enkelnukleotied polimorfismes) 
en kliniese isolate wat ‘n groot pncA delesie bevat vergelyk. Geen verskil is opgemerk in die tyd tot 
positiwiteit in MGIT media wanneer wilde tipe met die stam wat pncA mutasies bevat vergelyk is nie, 
wat daarop dui dat die pncA mutasies nie ‘n merkwaardige effek op fiksheid het nie. Stamme wat 
egter groot pncA mutasies bevat, het ‘n merkwaardige groei vertraging (p-waarde: <0.001) in vitro 
getoon. Hierdie effek het egter het nie die vermoë van hierdie stamme verander om oorgedra te word 
aan die gemeenskap nie. 
In ‘n poging om die diagnose van PZA weerstandigheid te vereenvoudig het ons die diagnostiese 
gebruik gemaak van ‘n “LATE-PCR” gebasseerde tegniek kombineer met fluoresserende merkers om  
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mutasies oor die hele pncA geen te identifiseer. Hierdie metode se sensitiwiteit en spesifisiteit was 
onderskeidelik 98.7% en 98.4%, wat daarop dui dat hierdie metode gebruik kan word in roetine 
laboratoriums, veral omdat daar van ‘n enkel-buis formaat gebruik gemaak word.  
Tesame het hierdie navorsing die kritieke gapings in kennis aangevul en het dit ‘n metode voorgestel 
wat die diagnose van PZA weerstandigheid kan vereenvoudig.  
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Mycobacterium tuberculosis is the causative agent of tuberculosis (TB) disease, an airborne infectious 
disease which is preventable and curable. According to the latest World Health Organization (WHO) 
TB report there were an estimated 9.6 million new cases of TB and 1.5 million deaths from TB 
globally each year (1). The current burden of TB on the health authorities can in part be attributed to 
drug resistance. Multi-drug resistant (MDR)-TB is defined as M. tuberculosis which has become 
resistant to at least two of front line anti-TB drugs: rifampicin (RIF) and isoniazid (INH) (1). The 
WHO estimates that between 360 000 and 600 000 MDR-TB cases occur among reported TB cases 
globally (1). Extensively drug resistant (XDR)-TB, the more severe and frequently fatal form of drug 
resistance, has been identified in various parts of the world, including in South Africa (2). XDR-TB is 
defined by the WHO as M. tuberculosis strains that are MDR and in addition, also resistant to a 
fluoroquinolone and one of the injectable drugs (kanamycin, amikacin and capreomycin). Resistance 
can be acquired, due to inadequate treatment (termed acquired resistance). Alternatively, resistance 
can be primary which means that already resistant bacilli were transmitted to the individual. Recent 
transmission plays a major role as the driving force of the drug resistant TB epidemic (3). It is 
important to control and reduce the rates of MDR-TB as it places a huge financial and public health 
burden on national TB control programmes world-wide (4). However, current efforts to control MDR-
TB are inadequate as only 25% of those diagnosed were placed on treatment (1).   
Central dogma suggests that resistance develops through a process of spontaneous mutation 
(synonymous single nucleotide polymorphisms (sSNPs)) in target genes, followed by antibiotic 
selection during periods of poor adherence or monotherapy. Resistance of M. tuberculosis to anti-TB 
drugs is thought to occur solely through mutations in target or related (e.g., pro-drug activating) genes 
(5). This concept is based on the close correlation of drug-resistance phenotypes with specific gene 
polymorphisms. Drug resistance develops spontaneously and is selected by exposure to sub lethal 
levels of antibiotics (6). It has been shown that resistance is due to chromosomal mutations in specific 
genes of M. tuberculosis (7). Evidence of drug resistance mechanisms has been provided by cloning 
and characterization of these specific genes in drug resistant isolates as compared to drug susceptible 
isolates (8). Thus the identification of these resistance conferring mutations has been proposed as a 
means to genetically identify drug resistance, in particular MDR-TB through the identification of 
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mutations in the rpoB gene (RIF), inhA promoter and katG gene (INH). Detection of mutations in 
these targets forms the basis for rapid diagnostics to reduce the time to diagnosis and thereby limit 
transmission of drug-resistance. 
The anti-TB drug pyrazinamide (PZA) is an integral component of the standardized TB treatment 
regimen for drug susceptible and drug resistant TB recommended by the WHO (1, 9). This is because 
of its unique ability to eradicate persister bacilli which are not easily eradicated with the other anti-TB 
drugs (10, 11). The importance of PZA has recently come to the forefront because this drug has been 
shown to deplete membrane energy and to inhibit trans-translation (12, 13). Both of these processes 
are thought to be essential for the survival of drug-tolerant persistent bacilli under various stress 
conditions (14). The addition of PZA to the treatment regimen for TB has allowed the duration of 
therapy to be shortened to 6 months and this drug has been credited with the success of the current 
directly observed therapy short-course (DOTS) strategy (10, 11).  
Diagnostic services are desperate for a molecular assay which can give rapid and accurate susceptibly 
and resistance information. However, the currently implemented GeneXpert MTB/RIF (Cepheid, 
Sunnyvale, CA) only detects TB and RIF resistance. Currently, there is no molecular assay for PZA 
resistance, and routine culture-based PZA susceptibility testing is not done in many parts of the world 
(including South Africa) due to the technical complexity of the assay. 
 
Pyrazinamide Susceptibility Testing Methods 
Culture-Based Pyrazinamide drug susceptibility testing  
Two commercial PZA drug susceptibility tests have been exhaustively evaluated: the BACTEC 
460TB System Mycobacterial Culture Media and the BACTEC MGIT 960 System (Becton Dickinson, 
Sparks, MD). A recent comparison of these methods showed that the BACTEC 460 system was more 
reliable for testing for PZA resistance as the authors observed that the BACTEC 960 system reported 
a number of false positives (15). A factor which influenced the scoring of false positives includes 
acidity of the media which may be titrated upwards by inoculum size (16-18). For this reason, the 
WHO has not approved a standardized culture-based method for PZA DST due to the complexity and 
inconsistency of the currently available culture-based tests (1, 19-21).   
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Pyrazinamidase activity assay  
This assay is based on the understanding that pncA encodes for the PZase enzyme. This enzyme is 
required to convert PZA into the active form of pyrazinoic acid (POA). It is hypothesized that 
mutations in the pncA gene substantially decrease PZase activity, thereby limiting the conversion of 
PZA to the active form of POA in M. tuberculosis (22) An PZase activity assay known as the 
Wayne’s method was developed by Wayne in 1974 which assesses the function of the PZase enzyme 
based on a colorimetric change (23). A modified method was also developed, whereby the critical 
concentration was changed from 100 µg/ml to 400 µg/ml and a slightly different media was used. A 
study performed by Miller et al (1995) found a very good correlation between the radio-metric 
BACTEC system and PZase (classic Wayne’s method) (24). They described a correlation of 98.2% 
and 100% in susceptible and resistant isolates respectively (24). A more recent study (2009) 
investigated the concordance of BACTEC 960 with both the classical Wayne’s method and the 
modified Wayne’s method (25). This study reported 88.9% concordance between BACTEC 960 and 
the classical Wayne’s method while 93.4% concordance between BACTEC 960 and the modified 
Wayne’s method. Both the studies show that the PZase activity assay can be used to detect PZA 
resistance but that resistance should be confirmed via culture-based DST. This method could be used 
as a screening test as suggested by the Sharma study (25).   
 
pncA genotyping  
Numerous studies have demonstrated that mutations in pncA are the primary mechanism of resistance 
to PZA (26-28). However, the correlation between genotype and phenotype is not so clear-cut. 
Extensive deoxyribonucleic acid (DNA) sequencing studies of pncA have revealed that numerous 
mutations and/or polymorphisms, which occur across the entire length of the gene, making it a 
complex target for the development of a genetic-based DST to identify causal mutations (29-32). This 
implies that sequencing the entire pncA gene is essential in order to capture all the possible mutations 
and to differentiate between non-synonymous and synonymous single nucleotide polymorphisms 
(SNPs). However, the identification of causal mutations is further complicated by the fact that not all 
non-synonymous mutations cause phenotypic resistance (33). Furthermore, sequencing 
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phenotypically PZA resistant samples has shown in a small percentage of these isolates that mutations 
in the pncA gene were absent (34, 35). This suggests that resistance could be conferred via an 
alternative mechanism(s). Consequently, there is conflicting evidence in the literature reporting the 
correlation between phenotype and genotype (5, 34-37). The sensitivities and specificities reported 
ranged from 41% to 100% and 67% to 100%, respectively. This could be explained by the reliability 
of the reference standard which as mentioned above is highly susceptible to pH and inoculum size (14, 
16, 17) and the critical concentration used. Alternatively, other mechanisms may be involved such as 
the gene rpsA (38). However, in a recent study reporting only a 45.7% correlation between genotype 
and phenotype also report no mutations could be identified in the rpsA gene (37). This suggests that 
rpsA may not be an alternative mechanism of PZA resistance. The authors cautioned against using 
genotypic results of pncA as the sole indicator that an isolate is resistant, and that DST should be used 
as the standard to define an isolate as PZA resistant.   
In order for a rapid genetics diagnostic test to be developed, the correlation between genotype and 
phenotype must be better understood. A meta-analysis performed in 2012 investigated the role of 
different techniques by evaluating their test performance (39). The study found a very good 
correlation between genotype and phenotype. The authors suggest that direct DNA sequencing of the 
pncA gene would allow for a more rapid turnaround time and a lower cost incurred may be useful 
when compared to the BACTEC radiometric system (39). A study which investigated PZA resistance 
observed an excellent correlation between genotype and phenotype (5). However there are studies 
which have seen a much lower correlation with no explanation as to why this might be (37). This 
suggests that more work should be done in order to better understand the mode of action and other 
possible mechanisms of PZA resistance. This highlights the various techniques which are currently 
employed to assess PZA resistance. Due to the lack of a standardized technique the global distribution 
of PZA resistance has not been described. 
 
Importance of Pyrazinamide 
Even though there are still many unanswered questions with regards to PZA, it will continue to play 
an important role in anti-TB treatment therapy. This point is highlighted by the fact that PZA is 
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included in the latest WHO update on MDR-TB treatment guidelines (9). PZA is also included in 
many clinical trials where researchers are investigating novel possible antibiotic combinations such as 
the PaMZ trial (40). These two clinically relevant facts indicate that PZA will continue to be an 
important antibiotic in the fight against not only drug susceptible TB but drug resistant TB.  
 
This thesis aims to further the current knowledge of PZA resistance in M. tuberculosis by addressing 
the following key knowledge gaps: 
1. Regional and global estimates of PZA resistance 
- Hypothesis: PZA resistance is more prevalent both regionally and globally then 
currently known.  
2. The prevalence of PZA resistance in different drug resistant cohorts (pan-susceptible to XDR-
TB) 
- Hypothesis: The prevalence of PZA resistance increases as the more resistance is 
gained. 
3. Mutations in the pncA gene which are not associated with PZA resistance 
- Hypothesis: Not all mutations in the pncA gene confer resistance at 100 µg/ml. 
4. The effect of different mutations in the pncA gene on the organism 
- Hypothesis: Different mutations in the pncA gene affect the fitness of M. tuberculosis. 
5. To investigate the possibility of a novel rapid genotypic diagnostic for PZA  
- Hypothesis: A rapid molecular diagnostic is possible using pncA as a marker for PZA 
resistance. 
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Structure of Thesis 
Each chapter is structured for potential publication. If the results in a specific chapter have not been 




The general introduction sets the tone for the thesis and introduces PZA and highlights the knowledge 
gaps and importance of this antibiotic.  
Chapter 2 
This published chapter serves to address a major knowledge gap, as it summarizes all literature of the 
prevalence of PZA resistance. The chapter provides regional estimates of PZA resistance as well as a 
global estimate. The review also addresses all mutations described in the literature that has been 
associated with PZA resistance.  
Chapter 3 
This published chapter comprises of a large data set of South African clinical isolates and illustrates 
the prevalence of PZA resistance from a pan-susceptible to XDR-TB; this chapter also demonstrates 
the correlation of genotypic to phenotypic data for predicting PZA resistance.  
Chapter 4 
This published chapter highlights mutations found in clinical isolates from both South Africa and the 
United States of America that were found to not confer resistance to PZA at the standard 100 µg/ml. 
This data is an important resource for researchers involved in designing novel rapid diagnostics for 
PZA.  
Chapter 5 
This chapter illustrates that different mutations in the pncA gene have an effect on the in vitro growth 
rate of the organism. While pncA is a non-essential gene, it is important to note that large deletions 
appear to affect the organism’s ability to grow, and this may have an effect on the ability of the 
organism to transmit, however this does not appear to be the case.  
Chapter 6 
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The chapter demonstrates a novel technique known as LATE-PCR coupled with Lights-On/Lights-Off 
probes to rapidly predict PZA resistance in a clinical isolate dataset. This technique shows highly 
promising results as a novel diagnostic.  
Chapter 7 
The general conclusion brings all the thesis chapters together and highlights how knowledge gaps 
described in the introduction have been addressed. This thesis has added significant value to the 
understanding of PZA resistance in M. tuberculosis.  
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Pyrazinamide (PZA) is crucial for tuberculosis (TB) treatment, given its unique ability to eradicate 
persister bacilli. The worldwide burden of PZA resistance remains poorly described. 
 
Methods  
Systematic PubMed, Science Direct and Scopus searches for articles reporting phenotypic (liquid 
culture drug susceptibility testing or pyrazinamidase activity assays) and/or genotypic (polymerase 
chain reaction or DNA sequencing) PZA resistance. Global and regional summary estimates were 
obtained from random-effects meta-analysis, stratified by presence or risk of multidrug resistant TB 
(MDR-TB). Regional summary estimates were combined with regional WHO TB incidence estimates 
to determine the annual burden of PZA resistance. Information on single nucleotide polymorphisms 
(SNPs) in the pncA gene was aggregated to obtain a global summary.  
 
Results 
Pooled PZA resistance prevalence estimate was 16.2% (95% CI 11.2-21.2) among all TB cases, 41.3% 
(29.0-53.7) among patients at high MDR-TB risk, and 60.5% (52.3-68.6) among MDR-TB cases. The 
estimated global burden is 1.4 million new PZA resistant TB cases annually, about 270,000 in MDR-
TB patients. Among 1,815 phenotypically resistant isolates, 608 unique SNPs occurred at 397 distinct 
positions throughout the pncA gene. 
 
Interpretation 
PZA resistance is ubiquitous, with an estimated one in six incident TB cases and more than half of all 
MDR-TB cases resistant to PZA globally. The diversity of SNPs across the pncA gene complicates 
the development of rapid molecular diagnostics. These findings caution against relying on PZA in 
current and future TB drug regimens, especially in MDR-TB patients.  
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The global burden of tuberculosis (TB) remains a major concern for health authorities worldwide. In 
2013, there were an estimated 9.0 million new cases and 1.5 million deaths from TB [1]. Treatment 
regimens for drug-susceptible TB consist of rifampicin (RIF), isoniazid (INH), pyrazinamide (PZA) 
and ethambutol (EMB). PZA forms a critical cornerstone of this regimen given its unique ability to 
eradicate persister bacilli, which allowed treatment shortening from 9-12 months to 6 months [2,3]. 
PZA will likely remain an important component of treatment regimens for drug-susceptible and 
multidrug-resistant TB (MDR-TB) because of its distinctive mode of action (interference with ATP 
production) [4,5] and its synergistic pharmacokinetic properties with two of the new anti-TB drugs: 
the diarylquinoline Bedaquiline (affects F1F0 proton ATP synthase) and the nitroimidazole PA-824 
(enhances PZA activity by altering the cell wall integrity) [6-8].  
PZase is only active at low pH (pH 5.00-6.00) as experienced in the phagosomal compartment. Down-
regulation of efflux pumps in the persister Mycobacterium tuberculosis results in intracellular 
accumulation of POA, which leads to the depletion of membrane potential [15-18], and inhibits trans-
translation [5]. The decreasing membrane potential is detrimental to non-replicating persisters whose 
energy requirements are finely balanced [9]. Trans-translation plays a role for stress survival and 
pathogenesis as it aids the management of stalled ribosomes, damaged mRNA and proteins during 
stressful conditions [15,19-21]. 
Even though PZA is a crucial component of TB treatment, little is known about the prevalence of 
PZA resistance, particularly on a global scale. PZA drug susceptibility testing (DST) is technically 
challenging and rarely performed as part of routine care or routine drug surveillance in resource-
limited settings. Two phenotypic PZA DSTs, BACTEC 460TB and BACTEC MGIT 960 (Becton 
Dickinson, Sparks, MD) exist; only BACTEC MGIT 960 is currently commercially available. Neither 
of these assays has been approved by the World Health Organization (WHO), likely due to their 
complexity and inconsistency, with frequent false positive results [22,23]. Classic and modified 
Wayne’s PZase methods, which assess the function of the PZase enzyme based on a colorimetric 
change at critical concentrations of 100µg/ml to 400µg/ml, respectively [24], are also not endorsed by 
the WHO. More recently, genotypic PZA assays have been developed based on observations that 
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mutations in the pncA gene are the primary mechanism of PZA resistance [14,15,25-27]. The pncA 
gene encodes the pyrazinamidase (PZase) enzyme, which converts PZA, a pro-drug, into the active 
pyrazinoic acid (POA) [14,15]. These molecular techniques, albeit not approved by WHO, are the 
most commonly used techniques in PZA drug resistance studies.  
Understanding regional differences in PZA resistance and its causal mutations is important for policy 
decisions regarding treatment regimens for drug-resistant TB and development of sequence-based 
diagnostics [26]. The aims of this review were to summarize the prevalence of PZA resistance 
globally and by WHO geographic regions, and to estimate the annual burden of PZA resistance, both 
stratified by MDR-TB status. We also summarize the global frequency and distribution of single 
nucleotide polymorphisms (SNPs) in the pncA gene in PZA resistant isolates.  
 
Materials and Methods 
Search strategy and selection criteria 
We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 
guidelines.[28] We searched PubMed, ScienceDirect and Scopus on July 14, 2014 for relevant articles 
published in the English language between 1998 and 2014 using an a priori protocol. The search 
terms “tuberculosis AND (pyrazinamide OR PZA) AND (phenotype OR genotype OR PZase OR 
pyrazinamidase OR pncA OR BACTEC OR mutations OR resistance OR resistant OR susceptibility 
OR sequence analysis OR microbial sensitivity tests OR molecular typing)” were used to identify 
articles reporting on PZA resistance using any of the methods of interest: phenotypic PZA DST, 
PZase activity assays, and/or genotypic PZA assays. Additional articles were identified from 
reference lists and review articles. 
Studies were eligible for inclusion in the meta-analysis of prevalence of PZA resistance if (1) PZA 
DST was assessed using at least one the following phenotypic tests: BACTEC liquid-based DST 460 
or 960, considered the reference standard for PZA DST, or PZase activity assays using classic or 
modified Wayne’s methods [24]. If both BACTEC 960 and BACTEC 460 results were reported, only 
the BACTEC 960 results were included. BACTEC 960 results were preferred to the BACTEC 460 
due to the BACTEC 460 no longer being commercially available. If results from BACTEC 460 using 
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both a PZA concentration of 100μg/mL and 50μg/mL were reported, the results using 100μg/mL were 
included. If results from both classical and modified Wayne’s PZase assays were reported, the 
classical Wayne’s results were included. Authors were contacted if no clear method of PZA DST is 
described in the article. To be eligible for inclusion in the analysis, studies had to provide information 
on the MDR-TB risk status (patients diagnosed with MDR-TB, patients at high-risk of MDR-TB, or 
inclusion of any TB case), reporting on a single subgroup or stratifying results by subgroup. High-risk 
of MDR-TB was defined as an isolate being resistant to at least one anti-TB drug. Any TB was 
defined as the inclusion of patients independent of drug resistance profile. 
Studies were eligible for inclusion in the descriptive SNP analysis if they performed genotypic testing 
using polymerase chain reaction (PCR) and DNA sequencing and characterized the found SNPs. 
For both the PZA prevalence and pncA SNP analysis, studies including samples from multiple 
countries were only included if the results were stratified by country. In studies collecting multiple 
samples from a single patient, only the first sample result was used. Where a study performed repeat 




M. W. and R. W. independently reviewed titles and abstracts of original studies retrieved by the 
search. M. W. and T. Y. reviewed full-text and references of selected articles. M. W. and H.M.S. 
abstracted study data from full reports.  
The following information, if available, was abstracted from each article: first author surname; 
publication year; WHO region (Africa, Americas, Eastern Mediterranean, Europe, South East Asia, or 
Western Pacific); study dates; study design; study setting; sample size; MDR risk subgroup; age; 
gender; HIV status; exclusion criteria; specimen type; phenotypic DST method; PZase activity assay; 
genotypic method; and whether the up and down stream regions of pncA were sequenced. The number 
of patients with PZA resistance according to liquid DST, the lack of PZase activity, or genotypic 
mutations in the pncA gene was also recorded. As Taiwan was not defined by the WHO, it was 
grouped in the Western Pacific region.  




Summary estimates for the prevalence of PZA resistance, calculated using random-effects meta-
analytic methods in STATA 13 (StataCorp LP, College Station, TX), were determined globally and 
for each WHO region, stratified according to whether the subgroup of patients had MDR-TB, were at 
high-risk of MDR-TB, or had any TB.  
Estimation of the burden of PZA resistant TB, stratified by region and by presence of MDR-TB were 
obtained by multiplying the regional point estimates obtained by the random-effects meta-analysis by 
the most recent (2011) regional WHO estimates for incident TB and MDR-TB cases [1]. 
The analysis of SNPs in the pncA gene was descriptive. We present results according to nucleotide 
position in order to identify regions of SNP clustering within the pncA gene. In addition, we present a 
detailed description of all SNPs reported, including the location and type of polymorphism and 
countries where this SNP has been isolated, as well as whether this SNPs has been linked to a resistant 
phenotype only or has been observed in both resistant and susceptible isolates, with phenotypic 
resistance defined by BACTEC DST results or the PZase enzyme assay results if BACTEC DST 
result was not available. 
Role of the funding source: The funders of the study (NIH and NRF) had no role in study design, data 
collection, data analysis, data interpretation, or writing of the report. The corresponding author had 





The literature search resulted in 1077 abstracts identified. Of these, 205 full-text articles were selected 
for review. In total, 62 [29-90] articles met the eligibility criteria for reporting PZA resistance, 
resulting in 91 datasets due to articles having isolates from multiple WHO regions as well as isolates 
which met different cohort type criteria (Fig. 1). Of the 205 full-text articles reviewed, 66 [27,59-123] 
articles were eligible for inclusion in the analysis of SNP frequency and distribution. 





Figure. 1. Flow diagram describing article selection.  
 
Phenotypic PZA Resistance: Study and Population Characteristics 
The 62 [29-90] final studies provided phenotypic PZA resistance data on 35,950 M. tuberculosis 
clinical isolates. According to WHO regions, 8 [39,59,60,68,69,78] studies were from African region, 
20 [29,30,38,40,41,43-47,59,70-72,79-83] from the Americas, 3 [31,48,80] from the Eastern 
Mediterranean, 20 [32,33,49-54,59,61,62,84-86] from European, 17 [34-36,47,55,56,59,63,73,80] 
from South East Asia, and 23 [37,42,57,58,64-67,74-77,80,86-90] from the Western Pacific region 
(Fig. 2). Most (53/91) [30,35,36,39-61,63,64,78-90] estimates of PZA prevalence were provided for 
studies including any TB patient, independent of drug resistance profile; 25 [29-37,42,59-67] studies 
reported PZA resistance among individuals with confirmed MDR-TB, and 13 [33,34,38,68-77] 
estimates were available for individuals at high-risk of MDR-TB. Study and population characteristics 
are displayed in S1 Table.  




Figure. 2. Global distribution of included studies. Countries are shaded if a study was included in 
this review.  
 
Phenotypic PZA Resistance: Regional and Pooled Prevalence’s and Annual Burden  
PZA resistance is prevalent across the entire globe and has been reported in all six WHO-defined 
regions (Fig. 3). The pooled summarized prevalence estimate of PZA resistance was 60.5% (95% CI 
52.3-68.6%) in MDR-TB patients, 41.3% (95% CI 29.0-53.7%) in TB patients at high-risk of MDR-
TB, and 16.2% (95% CI 11.2-21.2%) in studies including any TB patient irrespective of resistance 
profile. In all six WHO regions, the prevalence of PZA resistance was two to six times higher in 
MDR-TB patients compared to the population of all TB patients.  
 





Figure 3. Forest plot for the summary estimates of pyrazinamide prevalence by WHO region 
and presence or risk of MDR-TB. Abbreviations: CI, confidence interval; DST, drug susceptibility 
test; MDR-TB, multi-drug resistant tuberculosis; N/A, not applicable; WHO, world health 
organization. MDR-TB was defined as an isolate being resistant to RIF and INH. High risk of MDR-
TB was defined as an isolate being resistant to at least one anti-TB drug. *Any TB was defined as the 
inclusion of patients independent of drug resistance profile.  
 
PZA resistance prevalence among cases of MDR-TB ranged from 48.8% (95% CI 30.1-67.5%) in the 
Western Pacific to 80.0% (95% CI 65.7-94.3%) in the Eastern Mediterranean, but the latter estimate 
was based on a single study [31]. The estimated PZA prevalence among those at high risk of MDR-
TB varied greatly, from 24.0% (95% CI 9.9-38.1%) in the Western Pacific region to 75.0% (95% CI 
64.4-85.6%) in South East Asian region. In the general TB population, PZA prevalence estimated 
Stellenbosch University  https://scholar.sun.ac.za
25 
 
ranged from 11.4% (95% CI 1.6-21.2) in the European region to 21.9% (95% CI 12.0-31.9%) in the 
Americas. 
Multiplying the regional WHO estimates for the annual number of new TB cases and incident MDR-
TB cases by the pooled summarized prevalence estimates of PZA resistance, we estimated that about 
1.4 million PZA resistant TB cases occur annually, corresponding to 16.2% of the 9.0 million incident 
TB cases in 2013 (Table 1). Of these, an estimated 270,000 occur in people also resistant to at least 
isoniazid and rifampicin, representing 60% of all incident cases of MDR-TB estimated in 2013.    
 
Table 1. Estimated annual burden of new PZA resistant tuberculosis cases, overall and among 











African 2,600 000 416,000 78,000 45,800 
Americas 280,000 44,800 8,400 4,468 
Eastern 
Mediterranean 
750,000 120,000 27,000 21,600 
European 360,000 57,600 91,000 62,881 
South East 
Asian 
3,400 000 544,000 135,000 81,675 
Western Pacific 1,600 000 256,000 125,000 61,000 
GLOBAL 9,000 000 1,438 000 464,400 277,424 
Abbreviations: MDR-TB, multi-drug resistant tuberculosis; PZA, pyrazinamide; TB, tuberculosis; 
WHO, World Health Organization. 
* Incidence of TB cases from the World Health Organization Global Tuberculosis Report 2014. 
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Single Nucleotide Polymorphism Distribution in pncA gene  
The 66 [27,59-123] articles provided SNP data from 8,651 M. tuberculosis clinical isolates. 
According to WHO region, five [60,68,69,78,102] articles were from Africa, 14 [27,70-72,79,81-
83,97,100,105,107,114,120] from the Americas, two [80,92] from the Eastern Mediterranean, 17 
[61,62,84-86,93,96,103,104,106,108-110,115-117,119] from Europe, six [59,63,73,118,121,123] from 
South East Asia, and 22 [64-67,74-77,87-91,94,95,98,99,101,111-113,122] from the Western Pacific. 
A SNP in the pncA region was detected in the 1,815 of the 8,651 isolates, with 608 unique 
polymorphisms in 397 positions in the gene (S2 Table). SNPs were found throughout the entire pncA 
gene and flanking region with no particular clustering or hot spots (Fig. 4). There are however, a few 
SNPs which were found to be more frequently than others such as -11 and 195, but even the 20 most 
frequent SNPs only represented one third of all isolates with phenotypic PZA resistance. 






Figure 4. Distribution of reported single nucleotide polymorphisms (SNPs) throughout the pncA gene. Dashed lines indicate the open reading frame for 
the pncA gene.  
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M. tuberculosis resistance to rifampicin and isoniazid is well described and monitored, either through 
continuous surveillance or periodic surveys of a representative sample of patients [124]. In contrast, 
resistance to ethambutol and PZA, the other two front line drugs, is not routinely monitored and thus 
poorly described. In this systematic review and meta-analysis, we found that PZA resistance is 
ubiquitous and increases in prevalence as risk of resistance to other drugs increases, with pooled 
summary estimates for the prevalence of PZA resistance of 16.2% in the total population of TB 
patients, 41.3% among TB patients at high risk of MDR-TB, and 60.5% in patients with confirmed 
MDR-TB. The high prevalence of PZA resistance results in an annual estimated burden of 1.4 million 
new cases of PZA resistant TB, of which about 270,000 occur in patients with MDR-TB [1]. This 
high prevalence of PZA resistance observed in all regions of the world and across different TB patient 
groups is an important finding as PZA is not only a key component of all current regimens for both 
drug susceptible and drug resistant TB but is also included in all novel drug regimens currently 
undergoing evaluation in clinical phase II or III trials for treatment of drug-susceptible or drug-
resistant TB [125]. 
While our review aimed to comprehensively summarize information on PZA as a global public health 
problem, a different systematic review by Chang et al aimed to summarize the performance of 
molecular and PZase assays compared to culture-based phenotypic DST [126]. In that review, the 
median (range) of PZA resistance was 5% (0% to 9%) in non-MDR isolates and 51% (31% to 89%) 
in MDR M. tuberculosis isolates [126]. Our pooled prevalence estimates were higher than the median 
prevalence reported by Chang et al., especially in the overall TB patient population (16.2%). The 
summary estimate in our review may have overestimated the overall prevalence of PZA resistance 
among TB patients if the proportion of patients with drug resistance included in the studies was higher 
than that observed in the general population of the country where the studies took place.  
The high prevalence of PZA resistance and its inclusion in both standard and novel drug regimens 
highlights the need for routine PZA resistance testing. Others have suggested that molecular assays 
may be the way forward for detecting PZA resistance, based on findings that molecular assays 
targeting pncA can detect PZA resistance in MDR-TB isolates with high positive predictive values 




and rule out PZA resistance in non-MDR isolates with high negative predictive values [126,127]. 
However, DNA sequencing studies have revealed that mutations and/or polymorphisms occur across 
the entire length of the pncA gene, suggesting that sequencing the entire pncA gene would be essential 
to capture all possible mutations [109,117,127-129]. In this review, we confirmed that on a global 
scale, SNPs are distributed throughout the entire pncA gene. Whereas the tbdream database [15,26]  
previously reported on 278 unique polymorphisms prior to 2009, our systematic review provides an 
updated overview, with information on more than 600 unique polymorphisms in approximately 400 
positions in pncA (including the upstream flanking region). A few SNPs occurred more frequently 
than others, possibly because these SNPs are rooted in ancestral strains. Consequently, developing a 
molecular assay to detect PZA resistance will be much more challenging compared to other genes 
(rpoB, gyrA, embB) which have been found to have clear resistance-causing hot spots [130]. The 
identification of causal PZA mutations is further complicated by the fact that not all non-synonymous 
mutations cause phenotypic resistance [80] and that mutations in the pncA gene can be absent in a 
small percentage of phenotypically PZA resistant isolates, [66,102] suggesting that PZA resistance 
could be conferred via an alternative mechanisms such as mutations in the rpsA gene [81]. Whereas 
development of simplified micro-array systems for simultaneous detection of rifampicin, isoniazid 
and ethambutol resistance may be possible, [131] inclusion of assessment of PZA resistance may thus 
require a different approach such as targeted DNA sequencing or next generation sequencing 
[127,132]. 
A major strength of our study was the comprehensive inclusion of studies from across the globe and 
stratification of estimates by region and TB patient category. Insight into PZA prevalence by region 
and TB patient category provides essential information for the development and clinical use of future 
PZA resistance tests. Our study adds to the review by Chang et al, which was aimed at summarizing 
PZA resistance assay performance, not PZA resistance prevalence. Our review also complements the 
recent study by Miotto et al, which presented pncA sequence results of 1950 clinical isolates obtained 
from multiple laboratories, but did not stratify results by regions or MDR-TB status [127]. Our review 
was however limited by the data quality of the original studies [126]. Misclassification of PZA 
resistance may have occurred in the studies included, and due to false positive results, may have 




resulted in an overestimate of the true prevalence of PZA resistance. Phenotypic PZA drug 
susceptibility testing has not been endorsed by the WHO perhaps due to concerns surrounding false 
positivity related to the acidity of the media, inoculum size and critical concentration used 
[18,133,134]. Alternative techniques, the PZase activity assays, [24,135] have been used in the hope 
of identifying PZA resistance more accurately, but the interpretation of colourmetric change for these 
assays is highly subjective [56]. It is uncertain whether all mutations observed in the pncA region are 
associated with resistance. Similar to the tbdream database approach, [26] we chose not to make a 
priori decisions as to whether mutations described actually confer resistance and report any mutation 
found in a PZA-resistant isolate. Another limitation was the restricted number of studies for certain 
regions (especially Eastern Mediterranean, where all strains included came from a single study in 
Pakistan) and the lack of adequate representation of countries within certain regions (especially for 
Africa, where almost all isolates included came from South Africa, and the Americas). This not only 
resulted in uncertainty of the accuracy of the point estimates and wide confidence intervals but also 
highlights the lack of information on PZA resistance in several regions of the world. Finally, many 
studies did not provide clinical information and we were therefore unable to stratify our analysis by 
new versus re-treatment status. 
The ubiquitous presence of PZA resistance is of global interest and should signal a call to action. 
Development of rapid diagnostics to detect PZA resistance will be essential to maximize the efficacy 
of novel treatment regimens and minimize the risk of development of resistance to novel drugs. In 
addition, the high prevalence of PZA resistance, especially among MDR-TB patients, highlights the 
need for development of treatment regimens that can be effectively used in patients with PZA-
resistant MDR-TB.   
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S1 Table. Additional study and population characteristics. Abbreviations: MDR-TB, multi-drug 
resistant tuberculosis; PZA, pyrazinamide; TB, tuberculosis; WHO, World Health Organization; lab, 
laboratory; N/A, not applicable; N/S, not stated; HR-MDR, high-risk multi-drug resistant tuberculosis; 
MTB, Mycobacterium tuberculosis; PCR, polymerase chain reaction, East Med, Eastern 
Mediterranean 
S2 Table. Single-nucleotide polymorphisms (SNPs) detected in the pncA gene, by country and 
resistance phenotype. Abbreviations: A, adenine; bp, base pair; C, cytosine; del, deletion; G, guanine; 
R, resistant; SNP, single-nucleotide polymorphism; T, thymine.  
* Article found one isolate sensitive and one isolate resistant.  





Supplemental Table 1. Additional study and population characteristics. 
 






Cohort Type Sample 
Size 













Retrospective Lab N/A 54 Sputum N/A No PCR and DNA sequencing Minime-Lingoupou 2010 
Congo Retrospective Lab MDR 1 MTB clinical isolates BACTEC 460 (100μg/ml) Yes PCR and DNA sequencing Mestagh 1999 
Kenya Prospective Clinical Any TB 286 MTB clinical isolates BACTEC 960 (100μg/ml) No N/A Ndung’u 2012 
Rwanda Retrospective Lab MDR 1 MTB clinical isolates BACTEC 460 (100μg/ml) Yes PCR and DNA sequencing Mestagh 1999 



























MTB clinical isolates 
MTB clinical isolates 
MTB clinical isolates 
MTB clinical isolates 
MTB clinical isolates 
MTB clinical isolates 
BACTEC 460 (100μg/ml) 
N/A 
BACTEC 960 (100μg/ml) 
BACTEC 460 (100-900μg/ml) 
BACTEC 960 (100μg/ml) 







PCR and DNA sequencing 
Whole genome sequencing 
Ion Torrent 
PCR and DNA sequencing 
PCR and DNA sequencing 

































MTB clinical isolates 
MTB clinical isolates 
Sputum 
MTB clinical isolates 
MTB clinical isolates 
Indirect proportion method 
Proportion method 








PCR and DNA sequencing 
PCR and DNA sequencing 
PCR and DNA sequencing 
N/A 
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MTB clinical isolates 
































MTB clinical isolates 
MTB clinical isolates 
MTB clinical isolates 
MTB clinical isolates 
MTB clinical isolates 
MTB clinical isolates 
Middlebrook 7H11 
BACTEC 460 (100-300μg/ml) 
BACTEC 460/960 (100μg/ml) 
BACTEC 460 (100μg/ml) 
BACTEC 460 (100μg/ml) 







PCR and DNA sequencing 
PCR and DNA sequencing 
PCR and DNA sequencing 
PCR and DNA sequencing 
PCR and DNA sequencing 

















MTB clinical isolates 
BACTEC 960 (100μg/ml) 
BACTEC 460 (N/S) 
No 
No 




















MTB clinical isolates 
MTB clinical isolates 
MTB clinical isolates 
MTB clinical isolates 
N/A 
BACTEC 460 (100μg/ml) 






PCR and DNA sequencing 













































MTB clinical isolates 
MTB clinical isolates 
MTB clinical isolates 
MTB clinical isolates 
MTB clinical isolates 
MTB clinical isolates 
MTB clinical isolates 
MTB clinical isolates 
MTB clinical isolates 
BACTEC 460 (N/S) 
BACTEC 460 (100μg/ml) 
BACTEC 460 (100-900μg/ml) 
Middlebrook 7H11 
BACTEC 460 (100μg/ml) 
BACTEC 460 (100μg/ml) 
BACTEC 460/960 (100μg/ml) 
BACTEC 460 (6.25-50μg/ml) 










PCR and DNA sequencing 
N/A 
PCR and DNA sequencing 
PCR and DNA sequencing 
PCR and DNA sequencing 
PCR and DNA sequencing 
N/A 
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Iran Prospective Clinical N/A 49 MTB clinical isolates Middlebrook 7H9 Yes PCR and DNA sequencing Doustdar 2009 
Yemen Retrospective Lab Any TB 31 MTB clinical isolates Middlebrook 7H11 Yes PCR and DNA sequencing Hirano 1998 
Pakistan Prospective Clinical MDR 30 MTB clinical isolates BACTEC 960 (50-100μg/ml) No N/A Khurram 2012 
Saudi 
Arabia 






Abkhazia Prospective Clinical MDR 37 Sputum BACTEC 960 (100μg/ml) No N/A Pardini 2007 









MTB clinical isolates 
MTB clinical isolates 
BACTEC 960 (100μg/ml) 
BACTEC 460 (100μg/ml) 
No 
Yes 
PCR and DNA sequencing 
PCR and DNA sequencing 
Stoffels 2012 
Mestagh 1999 
France Retrospective Lab Any TB 35 MTB clinical isolates Middlebrook 7H10 Yes PCR and DNA sequencing Lemaitre 1999 
Germany Retrospective Lab N/A 9 MTB clinical isolates BACTEC 460 (100μg/ml) No PCR and DNA sequencing Napiorkowska 2014 

















MTB clinical isolates 
MTB clinical isolates 
MTB clinical isolates 
MTB clinical isolates 
BACTEC 460 (N/S) 
BACTEC 460 (100μg/ml) 
BACTEC 460/960 (100μg/ml) 













Latvia Retrospective Clinical N/A 28 MTB clinical isolates BACTEC 460 (N/S) No PCR and DNA sequencing Tracevska 2004 













MTB clinical isolates 
MTB clinical isolates 
MTB clinical isolates 
BACTEC 960 (100μg/ml) 
BACTEC 460 (100μg/ml) 




PCR and DNA sequencing 
N/A 












MTB clinical isolates 
MTB clinical isolates 
BACTEC 960 (100μg/ml) 
BACTEC 960 (100μg/ml) 
Yes 
No 
PCR and DNA sequencing 
PCR and DNA sequencing 
Portugal 2004 
Perdigao 2008 
Russia Prospective Clinical N/A 44 MTB clinical isolates BACTEC 460 (100μg/ml) Yes PCR and DNA sequencing Marttila 1999 
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MTB clinical isolates 
MTB clinical isolates 
MTB clinical isolates 
N/A 
N/A 




PCR and DNA sequencing 
PCR and DNA sequencing 












MTB clinical isolates 
MTB clinical isolates 
BACTEC 460 (100μg/ml) 
BACTEC 460 (100μg/ml) 
No 
No 
PCR and DNA sequencing 
PCR and DNA sequencing 
Aragon 2007 
Espasa 2012 













MTB clinical isolates 
MTB clinical isolates 
MTB clinical isolates 
BACTEC 460 (100μg/ml) 
BACTEC 960 (100μg/ml) 




PCR and DNA sequencing 
PCR and DNA sequencing 












MTB clinical isolates 
MTB clinical isolates 
BACTEC 460 (100μg/ml) 
BACTEC 460 (N/S) 
Yes 
Yes 
PCR and DNA sequencing 
PCR and DNA sequencing 
Brown 2000 
Yuksel 2009  
United 
Kingdom 

















































MTB clinical isolates 
Sputum 
MTB clinical isolates 
Sputum 
MTB clinical isolates 
MTB clinical isolates 
MTB clinical isolates 
MTB clinical isolates 





BACTEC 960 (100μg/ml) 
Proportion method 
BACTEC 960 (100μg/ml) 
BACTEC 960 (100μg/ml) 










PCR and DNA sequencing 
PCR and DNA sequencing 
PCR and DNA sequencing 
PCR and DNA sequencing 
N/A 
N/A 












East Timor Prospective Clinical MDR; HR-MDR 23 MTB clinical isolates N/A Yes N/A Kelly 2004 
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MTB clinical isolates 






























MTB clinical isolates 
MTB clinical isolates 
MTB clinical isolates 
MTB clinical isolates 
MTB clinical isolates 
Middlebrook 7H11 
BACTEC 960 (100μg/ml) 
BACTEC 960 (100μg/ml) 
BACTEC 960 (100μg/ml) 






PCR and DNA sequencing 
N/A 
PCR and DNA sequencing 
PCR and DNA sequencing 















































MTB clinical isolates 
MTB clinical isolates 
MTB clinical isolates 
Sputum 
MTB clinical isolates 
MTB clinical isolates 
MTB clinical isolates 
BACTEC 460 (100μg/ml) 
Proportion method 
BACTEC 960 (100μg/ml) 
N/A 
BACTEC 960 (100μg/ml) 
Proportion method 








PCR and DNA sequencing 
PCR and DNA sequencing 
PCR and DNA sequencing 
Long fragment qPCR 
PCR and DNA sequencing 
PCR and DNA sequencing 













Lab N/A 33 MTB clinical isolates BACTEC 460/960 (100μg/ml) Yes PCR and DNA sequencing Pandey 2009 














MTB clinical isolates 





PCR and DNA sequencing 
PCR and DNA sequencing 
Hirano 1998 
Cheng 2000 
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MTB clinical isolates 
Sputum 
MTB clinical isolates 
MTB clinical isolates 
Extrapulmonary MTB 













PCR and DNA sequencing 
PCR and DNA sequencing 
PCR and DNA sequencing 
PCR and DNA sequencing 
PCR and DNA sequencing 















MDR; Any TB 
Any TB 
MDR 





MTB clinical isolates 
MTB clinical isolates 
MTB clinical isolates 
MTB clinical isolates 
BACTEC 960 (100-300μg/ml) 
N/A 
BACTEC 960 (100μg/ml) 





PCR and DNA sequencing 
N/A 






Vietnam Retrospective Clinical Any TB 339 MTB clinical isolates N/A Yes Line probe Van Hung 2013 
Abbreviations: MDR-TB, multi-drug resistant tuberculosis; PZA, pyrazinamide; TB, tuberculosis; WHO, World Health Organization; lab, laboratory; N/A, 
not applicable; N/S, not stated; HR-MDR, high-risk multi-drug resistant tuberculosis; MTB, Mycobacterium tuberculosis; PCR, polymerase chain reaction, 
East Med, Eastern Mediterranean. 
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Supplemental Table 2. Single-nucleotide polymorphisms (SNPs) detected in the pncA gene, by 




SNP type Country and reference Phenotype linked to SNP SNP Frequency 
-71 1-bp deletion Korea1 R  5 
 2-bp deletion Korea1 R 1 
-71 & -11 1-bp deletion & A>G Korea1 R 2 
-71 & 20 1-bp deletion & T>G Korea1 R 1 
-71 & 56 
& 386 
1-bp deletion & A 
insertion & 10-bp 
insertion 
Korea1 R 1 
-71 & 58 
& 400 
1-bp deletion & G>A 
& G>A 
Korea1 R 1 
-71 & 67 1-bp deletion & C 
insertion 
Korea1 R 1 
-71 & 152 1-bp deletion & A>C Korea1 R 1 
-71 & 161 2-bp deletion & C>T Korea1 R 1 
-71 & 199 1-bp deletion & T>C Korea1 R 1 
-71 & 226 1-bp deletion & A>C Korea1 R 1 
-71 & 298 1-bp deletion & A>C Korea1 R 1 
-71 & 307 1-bp deletion & T>C Korea1 R 1 
-71 & 403 1-bp deletion & A>C Korea1 R 3 
-71 & 446 
& 501 
1-bp deletion & T 
insertion and T 
insertion  
Korea1 R 1  
-71 & 454 1-bp deletion & 10-bp 
deletion 
Korea1 R 1 
-71 & 478 1-bp deletion & A>C Korea1 R 1 
-16  AACGTA>GGCAGTT USA33 R 1 
-15 & 11 A>C & T>C Sweden57 R 1 
-13 G>T Canada64 R 1 
-12 T>C  South Africa3 , Netherlands41 R3,41 3 
 T>G  Russia4 R 1 
 T deletion Iran2 R 1 




-12 & 228 T>C & T>C Korea5 R 1 
-11 80-bp deletion Korea1 R 1 
-11 & 376 80-bp deletion & G>A Korea1 R 1 
-11 A>G  Korea1,5,6,7, Iran2, Russia4, 
Thailand8, Portugal9, Scotland10, 
Brazil49, Canada12,64, Peru13, 
China31,47, Sweden38, India50, 
Spain59, Poland66 
R1,2,4,5,6,7,8,9,10,12,13,31,38,47,49,50,59,64,66  62 
-11 & 483 A>G & G>A India50 R 1 
-11 & 535 A>G & A deletion India50 R 1 
-11 A>C Thailand8 R 1 
-10 T>C South Africa3 R 1 
-7 T>C USA33 R 1 
-7 & 340 T>C & A>G Japan14 R 2 
-3 C insertion Sweden57 *R/S 1 
1 561-bp deletion Japan46 R 1 
 11-bp deletion China15 R 1 
 8-bp deletion China15 R 1 
2 T>C Portugal9,35, Poland66 R9,35,66 9 
3 G>A Japan16, Netherlands41 R16,41 4 
 G>T Korea6 R 1 
7 G>C Iran2, Brazil11,17, France37 R2,11,17,37 4 
 G>T Taiwan18 R 1 
8 C>A Korea1, 20, Japan14,19,46  R1,14,19,20,46 6 
8 & 419 C>A & G>A Japan14 R 1 
11 T>C Korea1, Peru32, USA33, China34,47, 
Japan36 
R1,32,33,34,36,47 7 
 T>G Korea1,6 R1,6 2 
12 G deletion Cuba56 R 1 
12 & 421 T insertion & C>T Korea1 R 1 
13 AT insertion India58 R 2 
14 T>A Japan16,46 R16,46 2 
 T>G Japan16, India50 R16,50 3 
16 T>C South Africa21 R 1 
17 T>G Korea20, China34 R20,34 2 
 T>C Sweden38,57,61 R38,57,61 3 
19 G>A Peru13 R 1 




 G>T Korea6, Peru13 R6,13 2 
19 & 22 G>C & G>T Korea1 R 1 
19 & 403 G>C & A>C Korea1 R 1 
20 T>G Russia4, Yemen22, Brazil23,  
USA39 
R4,22,23,39 5  
 T>A Korea6 R 1 
 T>C Brazil11 R  1 
20 & 386 
& 517 
C insertion & 10-bp 
insertion & G deletion 
Korea1 R 1 
20 & 437 C insertion & C>T Korea1 R 1 
22 G>T Russia4, Belgium43 R4,43 2 
 G>A South Africa3, China34,  
Belgium43 
R3,34,43 4 
22 & 104 G>T & T>G South Africa3 R 1 
23 A>G Korea6,20, Spain59, Canada64 R6,20,59,64 5 
 A>C China31 R 1 
 TCG insertion Korea7 R 1 
24 C>G Japan46 R 1 
25 G>T South Africa24 R 1 
26 T>G Korea6, Japan14 R6,14 2 
 T>C Korea6 R 1 
28 C>T Russia4, Korea6,20, Brazil11,  
Latvia25, Belgium43 
R4,6,11,20,25,43 7 
 C>A Russia4, Spain59 R4,59 2 
 C deletion China15 R 2 
29 A>C Korea1,6,20, Myanmar22, China31,48, 
USA33,39, Japan36, Belgium43,  
Spain59, Singapore62, Poland 19,66 
R1,6,19,20,22,31,33,36,39,43,48,59,62,66 17 
 A>G Korea6, USA12, Peru32, Cuba56, 
Poland66 
R6,12,32,56,66 7 
29 & 295 A>C & T>G Korea6 R 1 
31 & 34 
& 290 
C insertion & G>T & 
G>A 
Korea1 R 1 
34 G>A Korea5, USA39, Italy40, China63 R5,39,40,63 7  
35 A>C Korea6,20 ,USA12, China15,47,  
Japan19, India58, Mexico26, Peru32, 
Canada64 
R6,12,15,19,20,26,32,47,58,64  20 




 A>G South Africa3 *R/S 9 
 G insertion South Africa3 R 2 
36 A>G Peru32 R 2 
37 T>C China31 R 1 
38 T>C France37 R 1 
40 T>C Korea1,5,6, South Africa3,24,60, 
Myanmar22, Japan46, China47 
R1,3,5,6,22,24,46,47,60 14 
 T>G Peru32 R 3  
 T deletion South Africa3 R 1 
41 G>A Korea6,7, Latvia25, China34 R6,7,25,34 4 
42 C>G Korea20 R 1 
 C>A Poland66 R 1 
42 & 307 C>G & T>C Latvia25 R 1 
42 & 535 C>A & A deletion India50 R 1 
46 G>A China47 R 1 
49 G>A China34, Singapore62 R34,62 2 
 1-bp deletion Korea20 R 1 
50 G>A Thailand22 R 1 
52 T>C New Zealand45 R 1 
 G insertion Canada12 R 1 
52 &161 T>C & C>T China31 R 1 
54 2-bp insertion Japan16 R 1 
56 T>C China15, New Zealand45 R15,45 2 
 T>G Thailand8  R 1 
 234-bp deletion Korea7 R 1 
57 & 62 
& 70 
3-bp deletion & 4-bp 
deletion & 5-bp 
deletion 
China48 R 1 
59 1-bp deletion China15 R 1 
59 & 232 1-bp deletion & G>A Japan14 R 1 
60 G deletion Netherlands41 R 1 
61 G insertion Italy40, China47 R40,47 2 
64 A deletion Thailand65 R 1 
67 1-bp deletion Korea20 R 1 
 C insertion Korea1 R 1 
68 G>C Taiwan18 R 1 




68-69 GT>TC Korea6 R 1 
71 G>A Turkey27, China31, Peru32 R27,31,32 5 
 G deletion China15, USA33,39 R15,33,39 5 
74 1-bp deletion Korea20 R 1 




CC>AA & C>G & 
C>A 
Korea6 R 1 
76 GC insertion Brazil17 R 2 
77 5-bp insertion Korea1 R 1 
 G deletion Korea6 R 1 
78 G>C India58 R 2 
80 T>C Thailand8, China47, India50 R8,47,50 4 
83 C>T Taiwan18 R 1 
84 C deletion Russia4 R 1 
89 C>A China51 R 1 
92 T>C Thailand8 *R/S 13  
 T>G Thailand8 *R/S 4 
94 T>G South Africa24 R 1 
96 & 338 C>T & G>T Russia42 R 3 
96 & 338 
& 362 
C>T & G>T & G>T Russia42 R 1 
98 A>C China34 R 1 
99 C deletion Sweden38 R 1 
100 T>G Japan14,16,46, Peru32 R14,16,32,46 6 
100 & 
400 
T>G & G>T Japan14 R 1 
101 A>G Iran2 R 1 
 A>C Thailand22 R 2 
102 C>A Korea5, Japan14 R5,14 2 
 C>G Netherlands41 R 1 
 167-bp deletion Turkey27 R 3 
103 C deletion Spain59 R 1 
104 T>C Thailand8, Japan46, Spain59 R8,46,59 4 
 T>G Brazil23 R 1 
106 ~5.3 kb deletion USA33 R 1 
107 CG insertion South Africa21 R 1 




108 C>G China47 R 1 
109 G>T South Africa24 R 3 
117 & 
169 
G>A & C>G Sweden38 R 1 
121 T>C China15 R 1 
123 C>G China15 R 2 
 C>A Thailand22, Peru32 R22,32 3 
128 A>C Thailand22, Belgium43 R22,43 3 
129 & 
493 
2-bp deletion & G>A Japan14 R 1  
132 A insertion Korea1 R 1  
134 T>A Korea1 R 2 
 T>G Korea6, Taiwan18 R6,18 2 
 T>C Thailand8, China34 R8,34 2 
135 G>C Taiwan18 R 1 
136 G>C South Africa24, Spain59 R24,59 2 
 G>T Thailand8 R 1 
 G insertion Yemen22 R 1 
 G deletion Brazil17 R 1 
137 C>A Korea1,6,12  R1,6,12 3 
 C>T Portugal9, Canada12,64, USA12,  
Korea12, Yemen22 
R9,12,22,64 9 
139 A>C China15, Korea20 R15,20 2 
 A>G Korea6, Mexico26, China31,  
USA33,39, Sweden38 
R6,26,31,38,39, *R/S33 12 
 A>T Russia4 R 1 
142 A>G Korea1, China47 R1,47 3 
143 A>C Peru32, Cuba56 R32,56 5  
145 G>A Korea20, Peru32 R20,32 28 
 G>C South Africa24 R 1 
 G>T China48 R 1 
145 & 
305 
G>C & C>T Mexico26 R 1 
146 A>T Russia4 R 1 
 A>G Russia4, Korea20 R4,20 2 
 A>C Korea6,20, Brazil23, Belgium43,  
Japan46 
R6,20,43,46, *R/S23 8  




150 80-bp deletion Korea20 R 1 
151 C>G China51 R 1 
 C>A Brazil17 R 1 
 C>T Scotland10 R 1 
 80-bp deletion Korea6 R 1 
152 A>C Portugal9, Korea20, Thailand22, 
Turkey27, USA33, Japan46,  
China47 
R9,20,22,27,33,46,47 10  
 A>G Brazil11, Thailand22, Peru32,  
Italy40, India50, Canada64  
R11,22,32,40,50,64 21 
153 C>A Japan19, Sweden38, USA39,  
Poland66 
R19,38,39,66 6 
 C>G Poland19,66, India58, Sweden61 R19,58,61,66 7 
153 & 
493 
C>A & G>A Japan14 R 1 
156 & 
546 
C>A & G>T India50 R 1 
157 G>A Japan19 R 1 
158 A>C Korea12 R 1 
 44-bp deletion China47 R 1 
 A deletion Korea6 R 1 
160 C>A China15 R 1 
 C>T Sweden38,61 R38,61 2 
161 C>G Japan16, Canada64 R16,64 2 
 C>T Japan14,19, Taiwan18,  
South Africa21,24, China34,47,  
Peru32, Sweden38,61, Spain59 
R14,18,19,21,24,32,34,38,47,59,61 15 
 C>A Brazil11, Korea20, China34 R11,20,34 3 
 C deletion Korea6 R 1 
161 & 
225 
C>T & T>C Mexico26 R 1 
165 T>A Taiwan18 R 1 
166 G>T Taiwan18 R 1 
167 A>G Taiwan18 R 1 
168 C insertion Taiwan18 R 1 
169 C>G Iran2, Korea6, Sweden38,57,  
USA39,55, New Zealand45, Japan46, 
R2,6,38,39,45,46,55,57,64 21 










C>G & C>T Canada64 R 1 
170 A>C Taiwan18, China34, Turkey44,  
Japan46 
R18,34,44,46 4 
 A>G Korea5, Brazil11, Canada64 R5,11,64 3 
 T insertion China34 R 1 
171 C>T Taiwan18 R 1 
172 T>C Korea6,7, Peru13, Sweden38,61 R6,7,13,38,61 6  
 T deletion South Africa24 R 12 
 2-bp deletion Brazil23 R 1  
173 T>C China31,47 R31,47 2 
174 C>A Taiwan18, South Africa30 R18,30 2 
 C>G Korea20, Canada22,64, Sweden38 R20,22,38,64 4 
 T insertion China34 R 1 





C>T & C>T Korea7 R 1 
181 A>C France37 R 1 
181 & 
416 
A>C & T>C Japan46 R 1 
182 5-bp insertion Brazil17 R 3 
 CA deletion Japan46 R 1 
184 C>A Latvia25, New Zealand45, China47 R25,45,47 3 
184 & 
290 
T insertion & G>T Japan46 R 1 
185 C>T Japan16, Korea20, Peru32, China63 R16,20,32,63 5 
 C>A Azerbaijan10, Taiwan18, Poland66 R10,18,66 3 
 C>G USA33 R 1 
188 A>G Yemen22, Latvia25, Belgium43, 
Canada64 
R22,25,43,64 5 
 A>C Mexico26, Belgium43,  
Singapore62 
R26,43,62 3 
 2-bp insertion Japan16, Peru32 R16,32 2 




 T insertion New Zealand45 R 1 
190 T>G Korea6,7 R6,7 2 
192 8-bp insertion Brazil23 R 3 
 A insertion France37, China48 R37,48 2 
193 A insertion Portugal9, Canada12, USA12 R9, 12 3 
194 & 
244 
C>G & C>T Turkey44 R 1 
195 C>T Iran2, India50, USA39, Sweden61 R2,39, *R/S50,61 19 
 68-bp deletion Azerbaijan10 R 1 
195 & -11 C>T & A>G India50 R 1 
195 & 11 C>T & T>G Canada64 R 1 
195 & 29 C>T & A>G India50 R 1  
195 & 43 C>T & T deletion Iran2 R 1  
195 & 
131 




C>T & A insertion & 
A deletion 
Korea1 R 1 
195 & 
202 
C>T & T>C USA39 R 1 
195 & 
282 
C>T & 2-bp deletion Canada64 R 1 
195 & 
314 
C>T & G>A India50 R 1 
195 & 
328 
C>T & G>T India50 R 1 
195 & 
329 
C>T & A deletion Thailand65 R 1 
195 & 
391 
C>T & G insertion Canada64 R 1 
195 & 
406 
C>T & G>A India50 R 1 
195 & 
408 
C>T & G insertion Canada64 R 1 
195 & 
422 
C>T & A>C Canada64 R 1 
195 & C>T & T>C India50 R 1 







C>T & GC insertion Sweden38 R 1 
195 & 
535 
C>T & A>C Iran2 R 1 
195 & 
535 
C>T & A deletion India50 R 1 
196 T>C Korea1, Russia4, China31 R1,4,31 3 
 14-bp insertion Korea20 R 1 
199  T>C Korea6, Thailand8, Canada22, 
Sweden38, China47,48, Canada64 
R6,8,22,38,47,48,64 7 
200 8-bp insertion India50 R 1   
200 & 
390 
C>T & GG insertion Thailand65 R 1 
202 T>C Korea1,6, Brazil17, South Africa24, 
Sweden38, China47,48 
R1,6,17,24,38,47,48 11 
 T>G Korea6, South Africa24, Mexico26, 
Poland66 
R6,24,26,66 10 
203 G>T Brazil11, Hong Kong28, Spain59 R11,28,59 5 
 G>C Korea1,6 R1,6 2 
 G>A Korea6,20, USA12 R6,12,20 4 
205 C>G Brazil23 R 1 
206 C>G Korea20, India58 R20,58 4  
 C>T France37 R 1 
207 ACC deletion Taiwan18 R 1 
211 C>T South Africa3,24, Taiwan18,  
Mexico26, Peru32, Belgium43,  
Canada64 
R3,18,24,26,32,43,64 8 
 C>G Thailand8 R 8 
 C>A China34, Belgium43 R34,43 2 
 3-bp deletion Korea20 R 1 
212 A>G Iran2, Korea7, Portugal9, USA33 R2,7,9,33 6 
 A>C Japan46 R 1 
 14-bp insertion Korea20 R 1 
213 T>A Korea1, Netherlands41 R1,41 3 
 T>G USA12 R 1 
 T deletion Brazil17 R 1 




214 T>C China15, Thailand22, Brazil23,  
India58  
R15,22,23,58 6  
215 G>A Thailand8, Brazil23,  
South Africa24 
R8,23,24 3 
 29-bp deletion France37 R 1 
216 C>A Korea20, China47 R20,47 2 
 C>G Japan19, Latvia25, Canada64 R19,25,64 4 
218 G insertion Netherlands41 R 1 
221 G insertion Scotland10 R 2 
222 G>C Thailand8 R 1 
223 T>C South Africa21 R 1 
225 & 
515 
T>C & T>C Mexico26 R 1 
226 A>C Korea1,6,20, Brazil17,23,  
South Africa21, Myanmar22,  
Latvia25, Mexico26, China31,34,47,63, 
Peru32, USA33, Portugal35, 
Netherlands41, India50, Cuba56,  
Spain59, Canada64 
R1,6,17,20,21,22,23,25,26,31,32,33,34,35,41,47,50,56,59,63,64 38 
 A>G Taiwan18 R 1 
227 C>T Korea6,7, Brazil23, Turkey44 R6,7,23,44 4 
232 G>A Korea5 R 1 
 G>T Peru32 R 1 
233 G>T Taiwan18 R 1 
 G>A Korea6, USA33 R6,33 2 




Korea20 R 1 
234 G insertion China34 R 1 
 4-bp insertion Korea5 R 1 
236 & 
360 
C>T & T insertion South Africa3 R 1 
239 A deletion Turkey44 R 1 
241 T>G China31,63 R31,63 3 
244 C>G Belgium43 R 1 
245 A>G USA12, Brazil17, China34,63,  R12,17,43,45,63, *R/S34 7 




Belgium43, New Zealand45 
 AT>GG China31 R 1 
245 & 
389 
A>G & T>C Korea20 R 1 
246 A>T Brazil17 R 1 
248 C>G Taiwan18 R 1 
249 T>G China34 R 1 
250 C insertion Portugal9,35 R9,35 7 
254 T>C Iran2, Korea6, China15, Taiwan18, 
Peru32, USA33,39, India58 
R2,6,15,18,32,33,39,58 15 
 T>G Korea6,12, Azerbaijan10, China15, 
Japan16, Latvia25 
R6,10,12,15,16,25 7 
 T>A Canada64 R 2 
258 18-bp insertion Peru32 R 1 
260 C>T Belgium43 R 2 
 C deletion Canada64 R 1 
 AC insertion Japan46 R 1 
260 & 
436 
C>T & G deletion France37 R 1  
261 2-bp insertion Japan14,16 R14,16 4 
263 C>A China15, Canada64 R15,64 2 
264 24-bp deletion USA55 R 1 
269 T>G South Africa24, Sweden38, USA55, 
Canada64 ,  
Thailand65 
R24,38,55,64,65 5 
279 106-bp insertion Peru32 R 1 
280 T>C China31, Peru32 R31,32 4 
281 T>C Mexico26, China31 R26,31 2 
 T>G Cuba56 R 1 
282 C>G Korea1 , Thailand65 R1,65 2 
 T insertion Portugal35 R 1 
285 C>A Portugal35 R 1 
 CA deletion Peru32 R 2 
286 A>G Russia4, Korea6,20, Portugal9,  
China31, India50 
R4,6,9,20,31,50 14 
 A>C Korea6 R 1  
 A>T South Africa3 R 1  




 A deletion Korea20 R 2  
287 A>C Brazil11,49, Korea20, China34,  
France37 
R11,20,34,3749 7 
 A>G Mexico26 R 1  
 A>T Italy40 R 1  
 T insertion Korea6, Canada22 R6,22 2 
288 G>T China15 R 2  
 G>C India58 R 37 
 G deletion USA39 R 1  
289 G>T South Africa3,21, Italy40, India50 R3,21,40,50 6 
 G>A Thailand8, USA12,33, Korea20,  
China34 
R8,12,20,33,34 8 
 G>C Netherlands41 R 1  
290 G>A South Africa3, Japan16,  
Taiwan18,29, USA33, China34,  
New Zealand45, Singapore62 
R3,16,18,29,33,34,45,62 8 
 T insertion Portugal9  R  1  
291 T>C Sweden57 R 2  
 T deletion Italy40 R 1  
292 G insertion Poland66 R 1  
293 10-bp deletion Peru32 R 1  
297 C>G Brazil17, USA33 R17,33 2 
 C>A Thailand22, Japan46 R22,46 2 
298 A>C China34 R 4 
 A>G Taiwan18 R 1 
300 & 
539 
C deletion & T>C Singapore62 R 1 
301 G deletion Korea12 R 1 
 A insertion China15 R 1 
303 A deletion Korea20 R 1 
304 G>A Russia4 R 1 
305 C>T South Africa3,60, Russia4, China34 R3,4,34,60 8 
306 C insertion France37 R 1 
307 T>G Canada64 R 1  
 T>C Korea6, Canada10, Latvia25,  
Sweden38 
R6,10,25,38 10 
 5-bp deletion Korea6 R 1 




308 A>T Latvia25 R 1 
 A>G Taiwan18, China34, France37,  
Poland66 
R18,34,37,66 4 
 A>C Korea6 R 2 
309 C>G Russia4, Korea6, Brazil17, South 
Africa24, Peru32, USA33  
R4,6,17,24,32,33 15 
 C>A Korea1, USA33, Cuba56 R1,33,56 4 
310 A>T USA55 R 1 
312 C>A Korea1,20 R1,20 2 
 C>G Thailand8,65, Yemen22 R8,22,65 4 
314 G>A Brazil11, Peru32, China34 R11,32,34 4 
 C insertion Brazil11 R 2  
315 G insertion South Africa3, Brazil17, China34 R3,17,34 4 
316 245-bp deletion Poland66 R 1  
317 CT insertion Korea7 R 1 
319 G>A South Africa24 R 1 
 G>T Taiwan18 R 1 
322 G>T Iran2 R 1 
 G>C Iran2, Brazil11, Korea20  R2,11,20 4 
334 A>T China34 R 1 
335 A>T Taiwan18 R 2 
337 G deletion Korea20 R 1 
338 & 
472 
G>A & G>A Korea5 R 1 
339 G insertion Canada64 R 1 
340 A>C Yemen22, South Africa24,  
Poland66 
R22,24,66 4  
341 C deletion Korea6,12 R6,12 2 
 1355-bp deletion France37 R 1 
346 C>G South Africa24 R 1 
347 T>G Korea1, Russia4, India50, Poland66 R1,4,50,66 11 
 T>C Peru32, Italy40, China63 R32,40, *R/S63 4 
350 T insertion Japan46 R 1  
352 7-bp deletion Taiwan29 R 1  
353 A>C China15 R 1  
355 T>A China34 R 2  
356 G>T Peru32 R 1  




357 G>A Korea6, Cuba56 R6,56 2 
359 T>G Iran2, Brazil11,49, New Zealand45, 
India50, Spain59 
R2,11,45,49,50,59 6 
 T>C Portugal9,35, Mexico26, Sweden57 R9,26,35,57 29 
 81-bp deletion Peru32 R 2  
359 & 
435 
T>G & G insertion Korea1 R 1  
361 C deletion Spain59 R 1  
362 G>C Korea6, China15,48   R6,15,48 3 
 G>A Thailand8 R 1 
364 C>T Taiwan18, South Africa21,60,  
Peru32 
R18,21,32,60 4 
368 G>C Sweden38,57,61 R38,57,61 3 
 G>T South Africa21 R 1  
 18-bp insertion Korea6 R 1  
 AG insertion China15 R 1  
373 G>T Thailand8, Sweden38,61,  
New Zealand45 
R8,38,45,61 4 
 9-bp insertion Korea20 R 1 
374 T>G Portugal9,35, Mexico26 R9,26,35 28 
 T>A Russia4, Sweden38 R4,38 3 
 16-bp deletion Japan14 R 1 
375 C insertion Mexico26 R 1 
 9-bp deletion Spain59 R 1 
377 GA insertion Peru32 R 1 
378 10-bp deletion China47 R 1 
379 G>A Iran2 R 1 
 G>T Thailand8, China34 R8,34 2 
 30-bp deletion Mexico26 R 1 
 11-bp deletion Russia4 R 1 
380 9-bp deletion Mexico26 R 1 
 11-bp deletion Korea20 R 1 
381 GG deletion Korea6 R 1 
 9-bp deletion Portugal35 R 1 
382 AG insertion Korea6,7 R6,7 2 
 8-bp deletion Japan36 R 1 
 9-bp deletion India50, Cuba56 R50,56 2 




383 T>G New Zealand45, Japan46,  
Sweden57 
R45,46,57 3 
 9-bp deletion USA39 R 1 
385 5-bp deletion Korea20 R 1 
 CG deletion Japan46 R 1 
385 & 
420  
T>G & GG insertion USA12 R 1 
386 T>G Brazil17 R 1 
 4-bp deletion Korea6 R 1 
388 9-bp insertion Brazil23, USA33 R23,33 2 
389 T>C Korea1, China34,47 R1,34,47 4 
 T>G Canada22, USA33 , Thailand65 R22,33,65 4 
 G insertion India50 R 1 
 GG insertion Korea20, South Africa24, India50 R20,24,50 12 
390 GG insertion Mexico26 R 1  
391 G>T Korea20 R 1  
 GG insertion Korea6, Portugal9, France37, 
Sweden38,57, Japan46, China47 
R6,9,37,38,46,47,57 8 
 G insertion Mexico26, China47, Poland66 R26,47,66 3 
392 G insertion Korea6, Portugal35 R6,35 2 
 GG insertion Canada64 R 1  
393 GT insertion Korea7 R 1  
 T insertion Korea7 R 1  
 1-bp deletion Korea1 R 1  
394 G>A South Africa3, Taiwan18, Japan19, 
China34, Sweden38,61  
R3,18,19,34,38,61 7 
395 G>T Iran2, Korea7  R2,8 3 
 G>A Portugal9, Taiwan18, Korea20, 
Myanmar22, France37, Canada64 
R9,18,20,22,37,64 7 
 G>C China31, Sweden38,57,61, India50 R31,38,50,57,61 5 
 9-bp insertion Canada64 R 1  
 17-bp deletion India22 R 1  
396 T insertion China48 R 1  
 TC insertion India58 R 3  
397 G insertion Taiwan29 R 1  
398 T>C Russia4, Japan19, Portugal35,  
China63 
R4,19,35,63 5 




 T>G Brazil11 R 1  
 T>A USA33 R 1  
 TT deletion South Africa21 R 1  
399 163-bp deletion Singapore62 R 1  
401 C>T Canada12, Peru13, Taiwan18,29,  
USA33 
R12,13,18,29,33 5 
403 A>C Korea1,6,7,20, China31, Peru32,  
USA33, Japan46, Poland66 
R1,6,7,20,31,32,33,46,66 22 
 A>G Taiwan18 R 1  
 CC insertion China15 R 1  
404 C>A Poland66 R 3  
406 G>A Korea6, Brazil54 R6,54 3 
 G>C Portugal9, Scotland10 R9,10 2 
 G>T Korea6 R 1 
 G deletion Korea6 R 1 
407 A>G Korea7,20, South Africa24,  
China31,63 
R7,20,24,31, *R/S63 6 
 C insertion Azerbaijan10 R 1 
 GC insertion Japan46 R 1 
408 A insertion Korea1, China63, Canada64 R1,63,64 3 
410 A>C Korea6, Bangladesh10, Japan14,  
Peru32, China47, India58 
R6,10,14,32,47,58 7 
 A>G USA33 R 2 
412 T>C Japan16,46 R16,46 2 
 G insertion Thailand8 R 1 
 T deletion Japan46 R 1 
413 G>A China15, Latvia25, USA33,  
Sweden38, India58 
R15,25,33,38,58 6 
 G>C Korea12 R 1 
414 T>A Korea20 R 2 
 T>C Brazil17 R 2 
 G insertion Korea6 R 1 
415 G>C China15,31, Mexico26, USA33,  
India58 
R15,26,31,33,58 6 
 G>A Korea6,12, South Africa24 R6,12,24 6 
 G>T Japan46 R 1 
415 & G deletion & C>T India50 R 1 





416 T>C China15,31,47, Taiwan18, Korea20, 
Malaysia22, South Africa30,  
Japan53, Cuba56, Poland66 
R15,18,20,22,30,31,47,53,56,66 13 
 T>G Thailand8, China31,34,48, USA33, 
Portugal35, Spain59,  
South Africa60, Singapore62 
R8,31,33,34,35,48,59,60,62 13 
418 G insertion Korea1,20 R1,20 3 
418 & 
446 
C>A & 8-bp deletion Canada12,64 R 24 
419 68-bp deletion France37 R 1 
420 G insertion USA12 R 2 
 GC insertion South Africa21 R 1 
421 C>T Korea6,7, Portugal9 R6,7,9 3  
422 A>C Korea1,6,20, Russia4, USA12,  
China31,47, India58 
R1,4,6,12,20,31,47,58 10 
 C deletion Brazil17 R 1  
424 A>G Myanmar22, China34,47, Poland66 R22,34,47,66 4 
425 C>A China15, Thailand22, Sweden38,61 R15,22,38,61 7 
 C>T Thailand8, Bangladesh10,Korea20,  
New Zealand45, India58 
R8,10,20,45,58 6 
426 AG insertion India58 R 1  
427 G>A Iran2 R 1  
 G>C Mexico26 R 1  
428 C>G Italy40 R 1  
 GG insertion Korea12 R 1  
430 GAG deletion Netherlands41 R 1  
 6-bp deletion Poland66 R 2  
436 G>A Korea6,20, Thailand8,52, China63 R6,8,20,52,63 7 
437 C>T India22 R 1  
439 CG insertion Portugal9,35 R9,35 4 
440 1-bp deletion Mexico26 R 1  
442 C>A Poland19, Turkey44 R19,44 2 
 C>T Taiwan18 R 1  
444 CG insertion Brazil23 R 1  
 12-bp insertion Sweden38,57 R38,57 2 
448 GC insertion Korea20 R 2  




449 G deletion Japan46 R 1  
451 T deletion Korea20 R 1  
452 T>C South Africa3, China34,63,  
Canada64 
R3,34,63,65 6 
 T deletion Korea6 R 1  
454 G>A Korea5 R 1  
456 T insertion Brazil54 R 2  
457 C>G Brazil23 R 1  
458 C>A USA33 R 1  
 C>T China47 R 2  
458 & 
474 
C>T & C>A China48 R 1  
460 A>G Korea1, South Africa3,60, Russia4, 
China34 
R1,3,4,34,60 5 
461 G>C Taiwan18 R 1  
463 G>T Korea20 R 1  
 G>A New Zealand45, Canada64 R45,64 3 
464 T>G Iran2, Korea6,12, Brazil11,17,49,  
Taiwan29, France37, Sweden38,57,61, 
Belgium43, Cuba56 
R2,6,11,12,17,29,37,38,43,49,56,57,61 18 
 T>C Korea20 *R/S 1  
 T insertion Italy40 R 2  
465 T insertion Korea6 R 2  
467 T>A Japan46 R 1  
470 T>G Korea1 R 1  
 T>C Poland66 R 2   
472 T>G Thailand65 R 1  
476 T>C South Africa3,24, Portugal9,  
China34 
R3,9,24,34 11 
 T>G Korea6,20, China31 R6,20,31 18 
478 A>C Iran2, Russia4 R2,4 3 
479 C>A Mexico26, Turkey27  R26,27 2 
480 TGAC insertion Korea6 R 1 
481 G>C Russia4 R 2 
484 G>A China63 R 1 
484 & 
494 
9-bp deletion & 2-bp 
deletion 
Japan16 R 1 




485 G>A Brazil17, Hong Kong28, China31,  
USA39 
R17,28,31,39 5 
 GT deletion Korea20 R 1  
486 T insertion Poland66 R 1  
 10-bp deletion Japan46 R 1  
487 10-bp deletion Mexico26 R 1  
488 T>C India50 R 1  
489 T insertion Korea1 R 1  
490 T>C Brazil11,49 R11,49 2 
 T deletion Peru32 R 5 
495 C insertion Brazil11 R 1 
497 1-bp insertion Japan16 R 1 
499 A>C China47 R 1 
501 CG insertion China15 R 1 
502 A>C Korea20, China31, Netherlands41, 
Spain59 
R20,31,41,59 6 
503 C>A USA12 R 1 
511 G>A Portugal9, Bangladesh10, USA33 R9,10,33 3 
 G>C India58 R 1 
512 C>A Korea1, Brazil17, China48 R1,17,48 5 
 C>T China63, Canada64 *R/S63, R64 3 
 C deletion Rwanda10 R 1 
513 GC deletion Korea7 R 1 
514 & 
515 
C>G & T>C Belgium10 R 2 
515 T>C Korea6, Canada22, Brazil23,  
USA33,39, Sweden38,61, China48,  
Cuba56, South Africa60 
R6,22,23,33,338,39,48,56,60,61 15 
 T>G Belgium43, Poland66 R43,66 5 
 T deletion South Africa3 R 1 
516 G insertion Netherlands41 R 1  
520 G>T Korea20 R 2 
521 A>G China31 R 1 
 GG insertion Thailand8 R 1 
 T insertion Peru32 R 1 
523 A>G Japan19, Brazil23, Belgium43,  
Poland66 
R19,23,43,66 7 




524 T>G Korea20 R 1 
 T>C Sweden38,61 R38,61 2 
525 G>A China31, Belgium43, Brazil54 R31,54, *R/S43 4 
529 A>C Taiwan18 R 1 
530 C deletion Belgium43 R 2 
531 6-bp deletion Poland66 R 3 
532 C insertion Korea6 R 1 
535 A>C Iran2, South Africa24 R2,24 3 
537 G>T Latvia25 R 1 
538 G>T Korea6, China47, India50,  
Canada64 
R6,47,50,64 5 
542 A deletion China34 R 1  
543 G>T South Africa24 R 1  
545 T>C France37 R 1  
551 G>A Taiwan18 R 1  
554 G>C South Africa24 R 8 
559 T>G India50 R 1  
564 G>C Brazil54 R 1  
572 G>A Iran2 R 1  
573 A>C Canada64 R 1  
582 T deletion South Africa3 R 1  
Abbreviations: A, adenine; bp, base pair; C, cytosine; del, deletion; G, guanine; R, resistant; SNP, 
single-nucleotide polymorphism; T, thymine.  
* Article found one isolate sensitive and one isolate resistant.  
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Pyrazinamide resistance is largely unknown in the spectrum of drug resistant phenotypes. We 
summarize data on PZA resistance in clinical isolates from South Africa. PZA DST should be 




Pyrazinamide (PZA) is a critical component of the first-line tuberculosis (TB) treatment regimen [1]. 
The unique ability of PZA to target subpopulations of persister bacteria has significantly reduced the 
treatment duration from 9-12 to 6 months [2]. The importance of PZA is further highlighted by its 
inclusion in the latest WHO recommended multi-drug resistant (MDR)-TB treatment regimen [3] as 
well as most novel MDR-TB regimens presently under investigation [4].  
Little is known regarding the prevalence of PZA drug resistance, largely because drug susceptibility 
testing (DST) of PZA is not yet standardized and thus not routinely implemented in high burden 
countries. The BACTEC Mycobacteria Growth Indicator Tube (MGIT) 960 system PZA (BD 
Diagnostic Systems, NJ, USA) recently became the reference technique, but concerns remain since 
false resistance may occur with this system [5]. False resistance may occur due to inoculum size or 
the presence of bovine serum albumin in the media of the MGIT 960 DST.[6]   
Mutations in pncA are the primary mechanism of resistance to PZA [7]. It is hypothesized that these 
mutations decrease pyrazinamidase (PZase) activity, thereby limiting the conversion of PZA to the 
active form of pyrazinoic acid (POA) [7]. A high sensitivity (92%) and specificity (93%) for PCR-
DNA sequencing when compared to the phenotypic DST supports the use of genotypic DST for the 
identification of PZA resistance [8]. Extensive DNA sequencing studies of pncA have revealed that 
mutations occur across the entire length of the gene, making it a complex target for a molecular 
diagnostic to identify all causal mutations [9, 10]. Furthermore, not all non-synonymous mutations 
cause phenotypic resistance [6], and mutations in the pncA gene are absent in a small percentage of 
phenotypically PZA resistant isolates [11] suggesting that resistance could be conferred via an 
alternative mechanism(s), such as the gene rpsA or panD [12, 13].  





Several studies have investigated the prevalence of PZA resistance in drug susceptible as well as 
MDR-TB isolates. In a recent meta-analysis, the prevalence of PZA resistance was 0 – 9% among 
drug susceptible and 31 – 89% among MDR-TB isolates [8]. Data is scarce on the prevalence of PZA 
resistance in RIF mono-resistant, INH mono-resistant, extensively drug resistant (XDR) and pre-XDR 
TB isolates. 
This study aimed to determine the association between mutations in the pncA gene and phenotypic 
resistance to PZA and to investigate the prevalence of PZA resistance across the spectrum of drug 
resistant isolates, from pan-susceptible TB to XDR-TB. 
 
Materials and Methods 
Study samples 
A convenience sample of 775 drug resistant clinical isolates classified as INH mono-resistant, RIF 
mono-resistant or MDR-TB by the National Health Laboratory Services (NHLS) was selected. 
Isolates came from across South Africa (Western Cape, Eastern Cape, Free State and Gauteng) and 
duplicates were excluded. Routine DST for INH and RIF at the NHLS was done using either MGIT 
culture or the GenoType MTBRplus (Hain LifeScience) line probe assay (LPA).  
 
Phenotypic DST of INH, RIF and PZA 
At the MRC Centre for Tuberculosis Research laboratory, all selected isolates were subjected to 
phenotypic INH, RIF and PZA susceptibility testing using the BACTEC MGIT 960 method (BD 
Diagnostic Systems, NJ, USA). Growth at a critical concentration of 0.1µg/ml INH, 1.0µg/ml RIF, 
and 100µg/ml PZA was used to define resistance [14]. 
 
Genotypic classification of isolates 
DNA sequencing of the gyrA and rrs gene was done to identify pre-XDR-TB and XDR-TB, as 
previously described [15]. DNA sequencing of the pncA, panD and rpsA genes were done to identify 
PZA resistance, as previously described [12, 13, 16]. No restriction fragment length polymorphism 
(RFLP) genotyping was performed. 







We used the Cochran-Armitage test in R to assess the presence of a trend in prevalence of PZA 
resistance by levels of resistance to other drugs. 
 
Results 
Phenotypic and genotypic characterisation of isolates 
Based on phenotypic and genotypic DST performed at the research laboratory, 80 (10.3%) isolates 
were classified as pan-susceptible, 98 (12.7%) as INH mono-resistant; 279 (36.0%) as RIF mono-
resistant, 224 (28.9%) as MDR-TB and 94 (12.1%) as pre-XDR and XDR-TB. Of the 80 pan-
susceptible and 98 INH mono-resistant samples, 96 were confirmed rifampicin susceptible by 
molecular methods (MTBDRplus, Xpert MTB/RIF, rpoB sequencing). Low level rifampicin 
resistance may have been missed among the 82 samples evaluated only by MGIT960 DST, possibly 
resulting in some misclassification of samples as rifampicin susceptible. 
Correlation of genotypic and phenotypic PZA resistance by level of resistance to other TB drugs 
Overall, 246 (31.7%) isolates had a polymorphism in the pncA gene: 29 (11.8%) synonymous single 
nucleotide polymorphisms (SNP), 126 (51.2%) non-synonymous SNPs, 80 (32.5%) insertions and 11 
(4.5%) deletions. Among all 775 isolates, 15 had discordant results between genotypic and phenotypic 
DST after considering SNPs known to not confer resistance to PZA at 100µg/ml [6]. Most 
discrepancies (10/15) were phenotypically resistant despite the presence of wild type pncA gene. The 
remaining 5 discrepancies were phenotypically susceptible with a non-synonymous change in the 
pncA gene (TTC13TGC, TGC72GGC, GCG102GTG, GTG139GGG). Using the phenotypic DST 
results as the reference standard, genotypic DST had an overall sensitivity of 95.0 (95% CI 92.1 - 98.0) 
and specificity of 99.1 (95% CI 98.4 – 99.9). The strong correlation between phenotypic PZA-
resistance and changes in the pncA gene was observed independent of the resistance profile to other 
TB drugs. DNA sequencing of the panD gene failed to identify any mutations, sequencing of the rpsA 
gene identified one synonymous mutation (CGA212CGC) not associated with resistance [12]. 
 






Phenotypic PZA resistance by level of resistance to other TB drugs 
Using the BACTEC MGIT 960 system, the number of isolates resistant to PZA at critical 
concentration of 100µg/ml was: 0 of 80 (0.0%) pan-susceptible isolates, 2 of 98 (2.0%; 95% CI 0, 4.8) 
INH mono-resistant isolates, 21 of 279 (7.5%; 95% CI 4.4, 10.6) RIF mono-resistant isolates, 88 of 
224 (39.3%; 95% CI 32.9, 45.7) MDR isolates, and 91 of 94 (96.8%; 95% CI 93.2, 100) pre-XDR-TB 
and XDR-TB isolates (Figure 1). The proportion of isolates with PZA resistance increased 
significantly with increasing resistance to other drugs (Cochran-Armitage test, p =< 0.0005).  
Figure 1. PZA resistance prevalence in different resistant phenotypes.  
 
Discussion 
We found a significant increase in the prevalence of PZA resistance with increasing level of resistance 
(pan-susceptible (0%) to pre-XDR and XDR-TB (96.8%)). These findings extend prior observations 
of low prevalence of PZA resistance in pan-susceptible but high prevalence of PZA resistance in 
MDR-TB isolates [8, 10]. Our findings strongly suggest that patients with pan-susceptible and INH 
mono-resistance benefit from inclusion of PZA in their treatment regimen and that PZA DST should 
be routinely performed in patients with RIF mono-resistance and MDR-TB. Lastly that the inclusion 
of PZA in treatment regimens for pre-XDR and XDR regimen is likely to cause more harm due to 





side effects than benefit since 97% (95% CI 93, 100) of all pre-XDR and XDR-TB isolates were 
resistant to PZA. 
Similar to other studies, we found an excellent correlation between phenotypic and genotypic DST 
with an overall sensitivity of 95.0% (95% CI 92.1 - 98.0) and a specificity of 99.1% (95% CI 98.4 – 
99.9). Only DST results generated in our laboratory were considered, I did not consider publications 
which reported resistance for certain mutations which I found to be susceptible. We further observed 
that this strong correlation was independent of the resistance profile to other TB drugs. Taken together, 
these observations provide mounting evidence supporting the use of genotypic instead of the slow and 
cumbersome phenotypic DST for PZA [10]. Use of genotypic DST could however result in some 
misclassification due to the existence of silent mutations and resistance not conferred by mutations in 
the pncA gene [6]. In our study, the occurrence of discordances was rare, similar to other studies 
findings [11]. Finally, the role of some pncA mutations is unclear as two mutations (GCG102GTG, 
GTG139GGG) were found to be susceptible in our study but resistant in another study [10].  
 
Conclusion  
The prevalence of PZA resistance is strongly correlated with resistance to rifampicin and increases 
with additional resistance in MDR and XDR-TB strains. The presence of rifampicin-resistance could 
then be considered as an indicator to perform DST to PZA. Consideration should also be given when 
defining the role of PZA in future TB treatment regimens. 
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Sequencing of the Mycobacterium tuberculosis pncA gene allows for pyrazinamide susceptibility 
testing. We summarize data on pncA polymorphisms which do not confer resistance at a susceptibility 
breakpoint of 100 µg/ml pyrazinamide in MGIT within a cohort of isolates from South Africa and the 
US Centre for Disease Control.   
 
Text 
Culture-based drug susceptibility testing (DST) using the BACTEC MGIT PZA 960 medium (Becton 
Dickinson, Sparks, MD) at 100 µg/ml is the current gold standard test for pyrazinamide (PZA) 
resistance (1). False resistance results are known to occur with this assay (1, 2), which could be the 
result of alkalinisation of the medium due to a high inoculum size or the presence of bovine serum 
albumin (3). The use of alternative susceptibility breakpoint concentrations or different media are 
additional factors that may contribute to disparities in PZA susceptibility results (4-6). A further 
limitation of culture-based methods is the long turnaround time, which can exceed 20 days (7-9). 
Molecular methods offer an alternative strategy for the detection of PZA susceptibility. These 
methods detect polymorphisms in the 561bp pncA gene, which encodes the pyrazinamidase (PZase) 
enzyme that is responsible for conversion of PZA (pro-drug) to pyrazinoic acid (active form) (10). 
More than 325 polymorphisms (single nucleotide polymorphisms (SNPs), insertions and deletions) 
throughout the entire length of the pncA gene and in the promoter region have been described, 
complicating molecular detection (11-14). A good correlation (sensitivity >90%) between pncA 
polymorphisms in circulating isolates and phenotypic susceptibility results have been observed for 
PZA (15-18). Incomplete correlation of pncA molecular results with culture-based PZA testing has 
been ascribed to poor reproducibility of the phenotypic test or the presence of alternative genetic 
mechanisms for resistance including polymorphisms in the rpsA gene (19, 20). Additionally, a few 
pncA mutations have been reported in the absence of phenotypic resistance (15), but the role of such 
mutations in PZA resistance has not been thoroughly investigated. This study aimed to collate data on 
pncA polymorphisms in clinical isolates which do not confer resistance at a susceptibility breakpoint 
of 100 µg/ml PZA. To capture the spectrum of pncA mutations not associated with phenotypic PZA 





resistance, we performed a comprehensive literature search. In the 77 papers reporting both genotypic 
and phenotypic PZA susceptibility (Supplemental Table S1), 77 different pncA polymorphisms in 71 
different codons were reported to have a PZA susceptible phenotype using either BACTEC MGIT 
PZA 960 (Becton Dickinson, Sparks, MD), BACTEC PZA 460 (Becton Dickinson, Sparks, MD) or 
the Wayne’s assay (21). Forty-seven (68.1%) of these polymorphisms have also been reported in 
PZA-resistant isolates. These inconsistent phenotypic results could due to technical difficulties of 
phenotypic PZA assays or MICs that are close to the breakpoint. Another 26 (33.7%) mutations were 
found in only one or two isolates suggesting these new mutations need to be characterized further to 
determine their role in PZA resistance.  
To further investigate the relationship between pncA mutation and PZA susceptibility we analysed 
clinical isolates from culture collections at the Centers for Disease Control and Prevention (CDC), 
Atlanta, USA (n = 185) and Stellenbosch University, South Africa (n = 865). For the CDC isolates, 
pncA had previously been sequenced and only isolates with mutant pncA were included in this study. 
For the SA isolates, the pncA gene was amplified and sequenced using the ABI3130XL genetic 
analyzer (Applied Biosystems, Foster City, CA 94404 USA). Polymorphisms in pncA were identified 
in 231 (26.7%) of the SA clinical isolates relative to the PZA susceptible H37Rv reference strain. All 
isolates harbouring pncA mutations (CDC and SA) were subjected to DST against PZA (BD PZA Kit) 
at a critical concentration of 100 µg/ml using BACTEC MGIT 960. This phenotypic testing identified 
7 of 185 (3.8%) CDC isolates and 42 of 231 (18.2%) SA isolates to have a susceptible PZA 
phenotype despite the presence of mutant pncA alleles. These results were confirmed by repeat pncA 
sequencing and repeat PZA DST. From these 49 isolates, 10 different pncA polymorphisms 
(synonymous, n = 2; non-synonymous, n = 8) were identified (Table 1). Six polymorphisms were 
newly identified in this study, while 4 corresponded to previously described pncA polymorphisms. Of 
these four, only Thr114Met was previously observed exclusively in susceptible isolates. The 
polymorphisms were not restricted to a defined domain but were broadly distributed throughout the 
pncA gene, with a distribution similar to that of resistance-causing mutations (22).  
To further explore PZA resistance, each of the 49 PZA-susceptible isolates identified in this study was 
subjected to PZA minimum inhibitory concentration (MIC) determination using PZA concentrations 





of 25, 50, 75 and 100 µg/ml in BACTEC MGIT PZA 960 medium. Six of the polymorphisms (all 
non-synonymous SNPs) showed an MIC between 50 and <100 µg/ml, 3 polymorphisms (2 were 
synonymous) were associated with an MIC < 25 µg/ml, and one polymorphism had an MIC<25 for 
one isolate and >50 for a second isolate (Table 1). It is important to note that most of the pncA 
polymorphisms associated with susceptible isolates (7/10) identified in this study had a PZA MIC 
between 50 and 100 µg/ml. Six of 10 pncA polymorphisms associated with susceptibility were present 
in more than one isolate. The reproducibility of the MIC determinations across different clinical 
isolates with the same pncA mutation supports the notion that these polymorphisms do not confer 
resistance above the breakpoint concentration. However, some of SNPs identified in this study were 
reported to confer resistance in other studies (Supplemental Table S1: References 1, 2, 24, 36, 50, 76). 
These conflicting results may be due to the PZA MICs for these isolates being close breakpoint or 
associated with technical difficulties of performing PZA DST on solid media (1, 2).  
We acknowledge that the clinical relevance of these polymorphisms on treatment outcome remain to 
be determined. In a recent report, a MIC > 50 µg/ml and < 100 µg/ml was associated with a poor 2 
month sputum conversion (relative risk of 1.5 (95% CI: 1.2-1.8)) compared with a MIC ≤ 50 µg/ml 
(23). Accordingly, the authors concluded that a PZA susceptibility breakpoint of ~50 µg/ml should be 
used for clinical decision making. However, one cannot exclude other factors which could have 
contributed to the observed delayed treatment response (23).  
Based on the current accepted PZA susceptibility breakpoint concentration of 100 µg/ml (1), not all 
pncA mutations necessarily confer resistance. We propose that genetic PZA drug susceptibility testing 
results should be interpreted based on known phenotype and genotype relationships at a susceptibility 
breakpoint of 100 µg/ml until further evidence is presented in support of any revision of the 
susceptibility breakpoint. Further studies are required to improve our understanding of the relationship 
between treatment outcome and pncA mutations.  





Table 1: Single nucleotide polymorphisms in pncA found to not be associated with PZA drug 












35 (104bp)  CTG – CGG  Leu – Arg
†
 >25 < 75 µg/ml   Stellenbosch  13 
37 (110bp)  GAA – GTA Glu – Val 50 µg/ml 
 
CDC 2 
65 (195bp)  TCC – TCT  Ser – Ser
†
 <25 µg/ml   Stellenbosch 
and CDC  
21 
96 (288bp)  AAG – AAA Lys – Lys <25 µg/ml   Stellenbosch 2 
110 (329bp) GAC – GGC Asp  – Gly 50 µg/ml CDC 1 
114 (341bp)  ACG – ATG Thr – Met
†
 <25 µg/ml   Stellenbosch  5 
*130 (389bp) GTG – GCG Val – Ala
†
 <25 µg/ml and 
>50 <100 µg/ml   
Stellenbosch  2 
163 (488bp)  GTG – GCG  Val – Ala >75 <100 µg/ml   CDC 1 
170 (509bp)  GCC – GTC  Ala – Val 75 µg/ml   CDC 1 
180 (538bp)  GTC – ATC  Val – Ile  75 µg/ml  CDC 1 
Abbreviations: Ala, Alanine; Arg, Arginine; Asp, Aspartate; bp, base pair; CDC, Centers for Disease 
Control; Glu, Glutamate; Gly, Glycine; Ile, Isoleucine; Leu, Leucine; Lys, Lysine; Met, Methionine; 
MIC, minimum inhibitory concentration;  Ser, Serine; Thr, Threonine; Val, Valine. 
*This polymorphism had one isolate with an associated MIC of <25 µg/ml and another isolate with an 
associated MIC of >50 <100 µg/ml.  
†
This mutation was also identified in literature search. 
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SNP type Codon 
Change 




















Europe (76) S 1 100%  
-33 G insertion Upstream Sweden (40) S 1  100%  
-13 G>T Upstream Canada (73), Europe (76) R (73), S (76) 2  50%  
-7 T>C Upstream Korea (6), USA (35), 
Thailand (55) , Europe (76) 
S (6), N/S (55), R 
(35,76)  
8 12.5%  
-3 C insertion Upstream Sweden (40,61), Europe 
(76) 




14 T>C Ile5Thr China (72) S 1  100%  
16 A>C Ile6Leu Europe (76) S 128 100%  
27 G>C Val9Val Peru (14) S 1  100%  
31 A>G Asn11Asp China (72) S 1  100%  
35 A>C Asp12Ala Cambodia (5), USA (13),  
China (16,50,72), Japan (20),  
Korea (7,21), India (27,62),  
Mexico (28), Peru (34),  
Canada (73) , Europe (76) 
N/S (5,27), R 
(7,13,16,20,21,28,34,50,
62,73,76), S (72) 
28  7%  
35 A>G Asp12Gly South Africa (3),  
Europe (76) 
R (3), S (76) 11 18%  
40 T>G Cys14Gly Korea (21), Peru (34),  
Belgium (45) 
S (21,45), R (34) 5 20%  
49 G>T Gly17Cys Kazakhstan (77) S 1 100%  
62 T>C Val21Ala Germany (75), Europe (76) N/S (75), S (76) 5 80%  
82 G>A Ala28Thr Netherlands (43) S 1 100%  
92 T>C Ile31Thr Thailand (9,55) *R/S (9), N/S (55) 21 43%  
92 T>G Ile31Ser Thailand (9), Europe (76) *R/S (9), R (76) 5 20%  
98 A>C Asp33Ala Taiwan (19), China (36) S (19), R (36) 2 50%  





104 T>C Leu35Pro Thailand (9), India (27),  
China (36), Japan (49),  
Spain (63), Europe (76) 
R (9,49,63,76), N/S (27), 
S (36) 
6 17%  
104 T>G Leu35Arg Brazil (24), China (72) R (24), S (72) 2 50%  
114 G>C Ala38Ala Europe (76) S 1 100%  
117 2-bp 
insertion 
Frameshift Korea (6) S 1  100%  
127 C>T His43Tyr Netherlands (43) S 1  100%  
134 T>C Val45Ala Thailand (9), China (36),  
Europe (76) 
R (9,36), S (76) 3 33%  
137 C>T Ala46Val Portugal (10),  
Canada (13,73), USA (13),  
Korea (13,21), Yemen (23), 
China (72), Europe (76) 
R (10,13,23,73), S 
(21,72,76) 
13  23%  
139 A>G Thr47Ala Korea (7), Mexico (28),  
China (33), USA (35,41,71),  
Sweden (40,67),  
Europe (76)  
R (7,28,33,40,41), S 
(35,67,71,76) 
50 80%  
143 A>C Lys48Thr Korea (6), Peru (34),  
Cuba (60), Europe (76) 
S (6), R (34,60,76) 10  10%  
146 A>C Asp49Ala Korea (7,21), Brazil (24),  
Belgium (45), Japan (49),  
Europe (76) 
R (7,21,45,49,76), *R/S 
(24) 
8 12.5%  
147 C>G Asp49Glu Brazil (24),  
Netherlands (43) 
S (24,43) 2 100%  
188 A>C Asp63Ala Mexico (28), Belgium (45),  
China (51), Russia (65),  
Singapore (69), Europe (76) 
R (28,45,69,76), S (51), 
N/S (65) 
9 11%  
191 A>C Tyr64Ser Belgium (45), Europe (76) S (45), *R/S (76) 3  67%  
193 T>C Ser65Pro China (72) S 1  100%  
195 C>T Ser65Ser Iran (2), South Africa (3,66),  
Japan (20), India (27,53,64),  
Sweden (40,61,67),  
USA (41), Tanzania (55),  
Canada (73) , Europe (76) 
R (2), S 
(3,20,40,41,53,61,64,66,
67,73,76), N/S (27,55) 





Ser65Ser &  
His51Arg 
India (64) S 1  100%  





199  T>C Ser67Pro Korea (6,7), Thailand (9),  
Canada (23), Sweden (40), 
China (50,51), Canada (73),  
Europe (76) 
R7,9,23,40,50,51,73,76, S (6) 10 10% 
201 TCG 
insertion 
Frameshift China (72) S 1  100% 
234 C>T Gly78Gly China (51) S 1  100% 
245 A>G His82Arg USA (13), Brazil (18),  
China (36,72),  
Belgium (45), New  
Zealand (48), Europe (76) 
R (13,18,45,48,72,76), 
*R/S (36) 
12  8%  
277 G>A Val93Met Kazakhstan (77) S  1 100% 
290 G>A Gly97Asp South Africa (3), Japan (17),  
Taiwan (19,31), USA (35),  
China (36,72), New   
Zealand (48),  
Singapore (69), Europe (76) 
R 
(3,17,19,31,35,36,48,69,
76), S (72) 
13 8%  
304-306 GCG>AGA Ala102Arg Europe (76) S 1 100%  
304 G>C Ala102Pro Cambodia (5), Europe (76) N/S (5), S (76) 3 33%  
305 C>T Ala102Val South Africa (3,66),  
Russia (4),  China (36,72),  
Europe (76) 
R (3,4,36,66) , S (72,76) 10 40%  
309 C>G Tyr103STOP Russia (4), Korea (7,21),  
Brazil (18), South  
Africa (25), Peru (34),  
USA (35), Europe (76) 
R (4,7,18,25,34,35,76), S 
(21) 
17 6%  
341 C>T Thr114Met South Africa (25) S 10  100%  
347 T>C Leu116Pro Peru (34), Italy (42),  
China (72), Europe (76) 
R (34,42,76), *R/S (72) 5 20%  
371 G>A Gly124Asp Netherlands (43) S 1  100%  
382 G>T Val128Phe China (72) S 1  100%  
389 T>C Val130Ala Korea (1,21), China (36,50) ,  
Europe (76) 
R (1,36,50,76), S (21) 5 20%  
401 C>T Ala134Val Canada (13), Peru (14),  
Taiwan (19,31), USA (35),  
Russia (65), China (72),  
Europe (76) 
R (13,14,19,31,35,76), 
N/S (65), S (72) 
9  11%  





403 A>C Thr135Pro Korea (1,7,8,21), China (33),  
Peru (34), USA (35),  
Belgium (45), Japan (49),  




76), S (45,60) 
41 5%  
404 C>G Thr135Ser Europe (76) S 1 100%  
407 A>G Asp136Gly Cambodia (5), Korea (8,21),  
South Africa (25),  
China (33,72), Peru (34),  
Thailand (55), Europe (76) 
N/S (5,55), R 
(8,21,25,33,72), S 
(34,76) 
11 27%  
410 A>G His137Cys USA (35), Europe (76) R (35), S (76) 4 50%  
419 G>A Arg140His Japan (15),  
South Korea (47) 

















Japan (15) S 1  100%  
427 G>A Ala143Thr Iran (2), Belgium (45),  
Europe (76) 
R (2), S (45,76) 4 75%  
460 A>G Arg154Gly Korea (1), South  
Africa (3,66), Russia (4),  
China (36,72), Europe (76) 
R (1,3,4,36,66), S (72), 
*R/S (76) 
8      25%  
462 G>T Arg154Ser Europe (76) S 3 100%  
464 T>C Val155Ala Korea6,21, Peru (14), China72  S (6,72), N/S (14), *R/S 
(21)  
6 66%  
470 T>G Val157Gly Korea (1), China (72),  
Europe (76) 
R (1,76), S (72) 4 25%  
475 C>G Leu159Val Europe (76) S 1 100%  
478 A>G Thr160Ala China (72), Europe (76) S (72), R (76) 2  50%  
503 C>T Thr168Ile Europe (76) S 2 100%  
511 G>A Ala171Thr Portugal (10),  
Bangladesh (11), USA (35),  
China (72) 
R (10,11,35), S (72) 4 25%  
512 C>T Ala171Val Scotland (11), China (72),  
Canada (73), Europe (76) 
S (11,76), *R/S (72), R 
(73) 
6 67%  
521 A>G Glu174Gly China (33,54) R (33) , S (54) 2 50%  





523 A>G Met175Val Japan (20), Brazil (24),  
China (36), Belgium (45),  
Thailand (55), Poland (75),  
Europe (76) 
R (20,24,45,75,76), S 
(36), N/S (55) 
14 7%  
525 G>A Met175Ile Korea (6), China (33),  
Belgium (45), Brazil (57),  
Europe (76) 
S (6), *R/S (45), R 
(33,57,76) 
15 13%  
529 A>C Thr177Pro Taiwan (19), China (36) R (19), S (36) 2 50%  
545 T>C Leu182Ser Korea (21), France (39),  
Europe (76) 
S (21), R (39,76) 3 33%  
545 T>G Leu182Trp Europe (76) S 1 100%  
559 T>G STOP187Gly India (53), Sweden (61) R (53), S (61) 2 50%  
559 T>C STOP187Arg China (72) S 1  100%  
Abbreviations: Ala, Alanine; Arg, Arginine; Asn, Asparagine; Asp, Aspartate; bp, base pair; Cys, 
Cysteine; Glu, Glutamate; Gln, Glutamine; Gly, Glycine; His, Histidine; Ile, Isoleucine; Leu, Leucine; 
Lys, Lysine; Met, Methionine; N/S, not stated; Phe, Phenylalanine; Pro, Proline; R, resistant; S, 
susceptible; Ser, Serine; SNP, single-nucleotide polymorphism; Thr, Threonine; Trp, Tryptophan; 
Tyr, Tyrosine; Val, Valine. 
* Article reported one isolate sensitive and one isolate resistant.  
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PZA is an integral component of the current standardized treatment regimen recommended by the 
World Health Organization for the treatment of TB, because of its ability to shorten treatment to 6 
months when combined with isoniazid, rifampicin and ethambutol. Deleterious mutations in pncA 
gene are the primary mechanism of resistance to PZA. Extensive sequencing studies of pncA have 
revealed that mutations, small insertions and deletions occur across the entire length of the gene. The 
impact of these mutations on the growth characteristics of Mycobacterium tuberculosis has not been 
investigated, which has resulted in contrasting views emerging in the literature. This study aimed to 
investigate the in vitro growth rates of isolates harbouring different pncA mutations with the aim to 
determine the impact on these mutations on growth rate as a surrogate for fitness.  
 
Methods 
Growth rates measured using BD BACTEC MGIT 960 time to positivity (TTP) were compared 
between isolates with and without pncA mutations (single nucleotide polymorphisms (SNPs) and 
large deletions) matched for resistance to other anti-TB drugs where possible. A one way ANOVA 
was used to determine significance.  
 
Results 
No difference was observed in the TTP in MGIT media when comparing wild type and strains 
harbouring pncA SNPs, thereby suggesting that pncA SNPs do not have a significant fitness cost. 
However, strains harbouring large deletions encompassing the pncA gene showed a significant growth 
deficit (p-value: <0.001) in vitro.  
 
Conclusion 
This study suggests that SNPs in the pncA do not influence on the growth of M. tuberculosis. In 
contrast, deletions encompassing the pncA gene retarded the in vitro growth rate. However, this 
growth deficit did not prevent these strains from transmitting in the community. This differs from 





previous studies which have suggested that in vitro growth rate is a surrogate for fitness cost which 
reduces the ability of M. tuberculosis to transmit. 






Several efforts have been made to determine the genetic constituents required for growth and survival 
of Mycobacterium tuberculosis by means of screening transposon site hybridization (TraSH) libraries 
(1-3). These studies reveal that a large proportion of genes are non-essential for growth and are able to 
harbour mutations, while still allowing survival of the pathogen. Deletion of a non-essential gene 
involved in converting a pro-drug to an active drug is an alternative mechanism of drug resistance. 
One such example is the pncA gene which has previously been reported to undergo deletion in clinical 
strains (4-6). pncA encodes pyrazinamidase (PZase), an enzyme that converts pyrazinamide (PZA) to 
its active form pyrazinoic acid (POA) (7). PZA is an integral component of the current standardized 
treatment regimen recommended by the World Health Organization for the treatment of TB, because 
of the shortening of treatment to 6 months when combined with isoniazid, rifampicin and ethambutol 
(8). Deleterious mutations in pncA gene are the primary mechanism of resistance to PZA (9). 
Extensive sequencing studies of pncA have revealed that mutations, small insertions and deletions 
occur across the entire length of the gene (10-12).  
Recent studies have demonstrated that mutations linked with drug resistance could result in a fitness 
cost for the organism (13-16). Most studies have focused on determining the impact of mutations in 
the rpoB and rrs genes (14, 15, 17). These studies have highlighted how different mutations have 
different effects on in vitro growth. Accordingly these mutations have been classified as either being 
high or low cost mutations. Importantly, compensatory mutations have also been identified which 
ameliorate the fitness cost associated of the rpoB or rrs mutations (17, 18). To date no studies have 
reported whether mutations in pncA have a fitness cost, although the authors of a recent systematic 
review suggested that PZA resistance has a low fitness cost due to the observed clustering of PZA 
resistant strains (19). This contrasts with the view of  den Hertog et al who suggested that pncA 
mutations induce a fitness cost which may impair the organism’s ability to transmit (20). Their 
opinion was based on the lack of extensive clustering of pncA mutations causing PZA resistance.   
This study aimed to investigate the in vitro growth rates of M. tuberculosis isolates harbouring 
different pncA mutations (SNPs and large deletions) with the view to determine the impact on these 
mutations on growth as a surrogate for fitness.  






Pyrazinamide resistant M. tuberculosis isolates 
In vitro selected PZA resistant mutants  
Spontaneous PZA resistant clones were selected on 7H10 media containing 100 µg/ml PZA (21) 
using a pan-susceptible M. tuberculosis Beijing genotype progenitor strain according to the method 
described by Morlock et al (22). Colonies were picked and sub-cultured in 5 ml OADC-enriched 7H9 
medium. A total of 74 clones were selected for further analysis. All clones were confirmed to be 
resistant to PZA using the PZA DST BACTEC Mycobacteria Growth Indicator Tube (MGIT) system 
(Becton Dickinson, Sparks, MD). 
 
Clinical PZA resistant strains  
Twenty-three clinical M. tuberculosis isolates harbouring large pncA deletions were identified in the 
local database of M. tuberculosis whole genome sequences (personal communication EM Streicher).  
In addition, a selection of phenotypically PZA resistant (n = 23) and susceptible clinical isolates (n = 
23) were selected. These isolates were selected based on their drug resistance profile to ensure that 
they matched the isolates with large pncA deletions. The mechanism conferring PZA resistance was 
determined using Sanger sequencing of the pncA gene (23).  
 
pncA Sanger sequencing 
Amplification and sequencing of the pncA gene was performed as described by Streicher et al (23). 
Briefly, the pncA gene was amplified with primers JpncAs Forward and JpncAs Reverse (Table 1) 
and a standard PCR mix of 1X Buffer, 0.75 μM of each primer, 0.8 mM dNTPs and 0.125 μl (0.625 
U) Taq polymerase (Qiagen, Germany). These primers were designed to amplify a wild type (WT) 
product of 738 bp that includes the full length of the pncA gene (561 bp), as well as 80 bp of the 
upstream sequence and 97 bp of the downstream sequence. The amplification protocol consisted of an 
initial activation step of 95°C for 15 minutes, followed by 50 cycles of 94°C for 30 seconds, 60°C for 
30 seconds, and 72°C for 1 minute and a final elongation step of 10 minutes at 72°C. PCR products 
were sequenced in both directions with the JpncAs Forward and JpncAs Reverse primers. 





Amplification was confirmed by the detection of a distinct fluorescent melting curve signature 
consisting of two maxima (±92°C and ±93.5°C, respectively) by high-resolution melting analysis. 
Isolates with pncA deletions failed to amplify. The DNA sequencing reaction was done on a 
GeneAmp 9700 thermal cycler (Applied Biosystems, Foster City, CA, USA. Sequences were 
analysed on the BioEdit sequence alignment editor (http://www.mbio.ncsu.edu/bioedit/bioedit.html) 
with H37Rv as the reference strain.  
The boundaries of the deletions were determined by Sanger sequencing. Briefly, PCR primers were 
designed to span the deleted region identified by whole genome sequencing (Table 1). Each boundary 
was amplified with the corresponding primers using a standard PCR mix containing 1X Buffer, 0.75 
μM of each primer, 0.8 mM dNTPs and 0.125 μl (0.625 U) Taq polymerase (Qiagen, Germany). The 
amplification protocol consisted of an initial activation step of 95°C for 15 minutes, followed by 35 
cycles of 94°C for 30 seconds, 62°C for 30 seconds, and 72°C for 1 minute and a final elongation step 
of 10 minutes at 72°C. Amplification and band size was confirmed by gel electrophoresis (data not 
shown). Each amplicon was Sanger sequenced using the corresponding primers (Table 1).   
 
PZA susceptibility testing 
All isolates (clinical and in vitro mutants) were assessed for PZA susceptibility using the non-
radiometric BACTEC MGIT 960 method as per the manufactures instructions (BD Diagnostic 
Systems, NJ, USA). This system makes use of modified test media which supports the growth of 
mycobacteria at a pH of 5.9. In order to distinguish between resistant and susceptible isolates a critical 
concentration of 100 µg/ml PZA was utilized. Briefly an isolate was cultured in BACTEC MGIT 
using OADC enriched media; this was considered the starter culture. Two days after the starter culture 
had reached the growth threshold (400 growth units), the PZA DST was prepared. A 1:10 dilution of 
the starter culture was made in a sterile saline solution. Two PZA MGIT tubes are prepared: the first 
is the growth control tube which was supplemented with 800 µl of enriched media (pH adjusted) and 
500 µl of the diluted starter culture. The second tube is the PZA tube which was supplemented with 
800 µl of enriched media (pH adjusted), 100 µl of PZA (to a final concentration of 100 µg/ml), and 
500 µl of undiluted started culture. The MGIT tubes were logged using the EpiCentre
TM
 system (BD 





BACTEC) and tubes were loaded into the BD BACTEC MGIT machine. Samples results were read 
continuously for 20 days. If no growth has occurred in the PZA containing tube the sample was 
considered to be PZA susceptible and if grow had occurred in the PZA tube prior to the growth 
control tube reaching the growth threshold (400 growth units) the sample was considered PZA 
resistant. Due to the nature of DST a standardization of inoculum size was utilized.  
 
PZA minimum inhibitory concentration (MIC) testing 
Representatives of the pncA large deletion isolates (where possible 2 isolates of each unique deletion) 
were selected for PZA MIC testing in order to determine level of resistance. Three concentrations of 
PZA (300 µg/ml, 600 µg/ml and 900 µg/ml) were tested using the PZA susceptibility testing method 
described above.  
 
Growth rates (time to positivity)  
Time to positivity (TTP) was determined by measuring the number of hours that it took for the PZA 
DST growth control of each isolate to reach 400 Growth Units as measured by EpiCentre
TM
 system 
(BD BACTEC) software. The TTP data was analyzed using GraphPad Prism. In order to determine 

















Table 1. Primers for amplification of the pncA gene and large deletion junctions. 
JpncAs Forward 5′ – GGCGTCATGGACCCTATA – 3′ 
JpncAs Reverse 5′ – GTGAACAACCCGACCCAG – 3′ 
881_del_For 5′ – CGATGGAACGTGATATCCCGC – 3′ 
881_del_Rev 5′ – CCTTTTCTGTCAGTGGCCGG – 3′ 
2181_del_For 5′ – CGATGGAACGTGATATCCCGC – 3′ 
2181_del_Rev 5′ – ATCCGTCATACAGGCCACCG – 3′ 
298_del_For 5′ – CGATGGAACGTGATATCCCGC – 3′ 
298_del_Rev 5′ – TGACCACTTCTCCGGCACAC – 3′ 
3667_del_For 5′ – GGCCCGTACCTTGATATCGGG – 3′ 
3667_del_Rev 5′ – ATCCGTCATACAGGCCACCG – 3′ 
3548_del_For 5′ – GGCCCGTACCTTGATATCGGG – 3′ 
3548_del_Rev 5′ – ATCCGTCATACAGGCCACCG – 3′ 
17133_del_For 5′ – GATCCGTCGATGCCCACCAA – 3′ 
17133_del_Rev 5′ – CATGGGACGGGTTTTCGCTG – 3′ 
 
Results 
A total of 74 colonies were picked from the PZA 100 µg/ml 7H10 plates, termed in vitro (IV) mutants. 
Five of the 74 (6.8%) were contaminated while the remaining 69 (93.2%) were successfully amplified 
and the pncA gene was sequenced as well as having a PZA DST result (Supp Table 1). Twenty-four 
(34.8%) IV mutants which showed a WT genotype for pncA were found to be resistant to PZA at 100 
µg/ml. The remaining 45 (65.2%) IV mutants were found to have mutations in the pncA gene, 
spanning the entire length of the gene. A total of 29 different pncA mutations (which have been 
described in clinical isolates previously), including single nucleotide polymorphisms (SNPs); 
insertions; deletions and double SNPs were identified (Supp Table 1). All IV mutants with pncA 
mutations were confirmed to be resistant to PZA at 100 µg/ml.  





Twenty three clinical isolates harbouring large deletions encompassing the pncA gene were selected, 
termed Δ pncA. These deletions ranged in size; 299 bp, 881 bp, 2181 bp, 3455 bp, 3668 bp and 17133 
bp. These deletions were initially detected by means of whole genome sequencing (WGS) and the 
boundaries were confirmed using Sanger sequencing of the deletion junctions. Details of the deletions 
are shown in Supplemental Table 2 and visually illustrated in Figure 1. All the pncA deletions had a 
PZA MIC of >900 µg/ml (Supp Table 2).  
A total of 46 clinical isolates were selected of which 23 (Supp Table 4) were susceptible to PZA 
(termed WT pncA) and 23 (Supp Table 3) were resistant to PZA (termed MUT pncA). The PZA 
susceptible isolates were all confirmed to have a pncA wild type genotype and the PZA resistant 
isolates were all confirmed to have a mutation in the pncA gene. The 46 clinical isolates (XDR-TB) 
were matched according to drug resistance profile with the strains harbouring pncA large deletions 
(XDR-TB). The resistant clinical isolates had 23 different mutations in the pncA gene; 21 non-
synonymous SNPs and 2 insertions (Supp Table 3).  
To determine the influence of mutation in the pncA gene on TTP the following comparisons were 
made: 1) WT pncA vs IV mutant’s; 2) IV mutant’s vs MUT pncA; 3) IV mutant’s vs Δ pncA; 4) MUT 
pncA vs Δ pncA, 5) WT pncA vs MUT pncA, 6) WT pncA vs Δ pncA. Figure 2 shows a graphic 
representation of the difference in TTP for each of the groups. The mean TTP for each group is as 
follows, 203 hours for the Δ pncA group, 143 hours for the MUT pncA group, 129 hours for the IV 
mutant’s group, and 121 hours for the WT pncA. A significant difference (p value: <0.001) was 
observed between the growth rate of the Δ pncA isolates were compared to the growth rates of the 
MUT pncA isolates, IV mutant’s and the WT pncA isolates. However, no significant difference was 
observed when the growth rates of the MUT pncA isolates and IV mutants were compared, or when 
the WT pncA isolates and MUT pncA were compared or when the WT pncA isolates and the IV 
mutant’s were compared. 
 
Discussion  
Using TTP in combination with a standardised inoculum, we are unable to show a significant 
difference in growth rate between WT strains and strains harbouring pncA SNPs or small indels or IV 





mutants. This suggests that the loss of pyrazinamidase activity does not influence in vitro growth rate 
which is in line with previous findings that have demonstrated that the pncA gene is not essential for 
in vitro growth (11, 24). Furthermore, molecular epidemiological studies conducted in South Africa 
(25, 26), USA (27) Belgium (19), and Russia (28) confirm that strains harbouring pncA mutations 
retain their ability to transmit. Together this suggests that pncA mutations do not have a fitness cost. 
These findings support the observation that pncA mutations have a low fitness cost according to 
Stoffels et al (19). This is in contrast to the views of den Hertog et al who suggested that PZA 
resistance induces a fitness cost that impairs M. tuberculosis transmission (20).  
We identified a significant difference in the in vitro growth rate between strains harbouring deletions 
encompassing the pncA gene. This growth deficit was not dependent on the size of the deletion, 
suggesting that altering the spatial arrangement of the genes surrounding the pncA gene has an 
influence of in vitro growth rate. The slower growth rate of these strains suggests that they may have 
an impaired ability to transmit as has been suggested for other high fitness cost drug resistance 
causing mutations (13). However, two clusters (more than one isolate with the same deletion 
boundary) were identified among the 23 isolates with large pncA deletions. Interestingly, the 881 bp 
pncA deletion was present in isolates from 17 patients thereby confirming the transmissibility of this 
strain. Transmission of these strains was further supported by the fact these deletions had identical 
boundaries and were of the Beijing genotype. 
We acknowledge that this study has certain limitations. Firstly, we cannot exclude the possibility that 
other mutational events could have impacted on the in vitro growth rate in isolates harbouring large 
pncA deletions. This is unlikely given that 17 of the 23 isolates were from the same genetic 
background. Secondly, the growth rates were not compared in the same tube (a competition assay). 
Thirdly, the MGIT TTP is a relatively crude assessment of growth. The latter limitations could be 
addressed using molecular cloning to generate pncA deletions into the same progenitor strain. The 
competition assay would be a more accurate assessment of fitness cost.  
In conclusion this study suggested that SNPs and small indels do not influence in vitro growth rate. In 
contrast, large pncA deletions significantly slow the in vitro growth rate but do not prevent the 
transmission of these strains. This suggests a disconnect between in vitro growth rate and in vivo 





transmission. This differs from previous studies which have suggested that in vitro growth rate is a 
surrogate for fitness cost and the inability to transmit (14, 15, 29-31). This may be related to the 
difference in essentiality of the genes being tested. 
 




















Figure 1. Visual illustration of large deletions encompassing the pncA gene (Rv2043c) in clinical isolates of M. tuberculosis. Light grey areas indicate 
deletions and black areas indicate intact genomic regions relative to H37Rv. Genes are indicated with Rv numbers and the region included spans from 
nucleotides 2270750 to 2294526.   
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Figure 2. Average number of days to reach growth threshold of 400 growth units for Δ pncA, MUT 
pncA, IV mutant, and WT pncA, respectively. A one way ANOVA test was utilized.  
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Supplemental Table 1. IV mutant spontaneous M. tuberculosis isolates. 
Sample pncA SNP Phenotypic PZA DST Time to positivity 
(hours) 
1 Gln9Lys Resistant 122 
2 Tyr99STOP Resistant 147 
3 Tyr34STOP Resistant 176 
4 Tyr34STOP Resistant 148 
5 Tyr34STOP Resistant 125 
6 Tyr34STOP Resistant 160 
7 His57Asn Resistant 149 
8 CONTAM CONTAM CONTAM 
9 Trp68Gly Resistant 108 
10 Tyr34STOP + 
Tyr99STOP 
Resistant 155 
11 Trp119Cys Resistant 159 
12 Thr160Lys Resistant 97 
13 Thr160Lys Resistant 122 
14 Ser18STOP Resistant 132 
15 Val7Phe Resistant 114 
16 Tyr99STOP Resistant 119 
17 INS 146 (T) Resistant 156 
18 Gln10Arg + Glu91STOP Resistant 118 
19 INS 100 (C) Resistant 100 
20 Glu127STOP Resistant 125 
21 Ala102Val Resistant 108 
22 Ser18STOP Resistant 148 
23 Tyr34STOP Resistant 97 




24 Trp68Leu + Ala146Thr Resistant 99 
25 WT Resistant 148 
26 CONTAM CONTAM CONTAM 
27 DEL 128 (8bp) Resistant 121 
28 Cys14STOP Resistant 152 
29 Tyr103STOP + 
Val139Met 
Resistant 156 
30 Ser18STOP Resistant 125 
31 Ala102Val Resistant 162 
32 Tyr99STOP Resistant 160 
33 INS 131 (G) Resistant 122 
34 INS 131 (G) Resistant 151 
35 Gln10Lys Resistant 131 
36 WT Resistant 186 
37 WT Resistant 114 
38 WT Resistant 165 
39 WT Resistant 132 
40 Tyr34STOP Resistant 124 
41 WT Resistant 100 
42 Tyr34STOP Resistant 121 
43 WT Resistant 122 
44 Tyr99STOP Resistant 132 
45 WT Resistant 123 
46 Asp12Asn Resistant 106 
47 WT Resistant 108 
48 WT Resistant 143 
49 Ala26Asp Resistant 142 




50 Ala144Pro Resistant 149 
51 Trp68STOP Resistant 146 
52 INS 134 (A) Resistant 132 
53 WT Resistant 119 
54 WT Resistant 98 
55 WT Resistant 124 
56 WT Resistant 151 
57 Gln10His Resistant 155 
58 WT Resistant 122 
59 WT Resistant 128 
60 WT Resistant 122 
61 WT Resistant 100 
62 WT Resistant 132 
63 WT Resistant 114 
64 INS 70 (G) Resistant 143 
65 CONTAM CONTAM CONTAM 
66 CONTAM CONTAM CONTAM 
67 CONTAM CONTAM CONTAM 
68 His49Asn Resistant 127 
69 Tyr99STOP Resistant 122 
70 WT Resistant 123 
71 WT Resistant 180 
72 WT Resistant 166 
73 WT Resistant 124 
74 Ile45Ser Resistant 145 
 
 




Supplemental Table 2. Δ pncA clinical M. tuberculosis isolates.  








1 17133 bp Resistant (MIC >900) 171 XDR-TB 
2 3668 bp Resistant (MIC >900) 194 MDR-TB 
3 3455 bp Resistant (MIC >900) 204 MDR-TB 
4 881 bp Resistant 239 XDR-TB 
5 881 bp Resistant 169 XDR-TB 
6 881 bp Resistant 195 XDR-TB 
7 881 bp Resistant 160 XDR-TB 
8 881 bp Resistant 173 XDR-TB 
9 881 bp Resistant 234 XDR-TB 
10 881 bp Resistant 152 XDR-TB 
11 881 bp Resistant 251 XDR-TB 
12 881 bp Resistant 317 XDR-TB 
13 881 bp Resistant 376 XDR-TB 
14 881 bp Resistant 149 XDR-TB 
15 881 bp Resistant 226 XDR-TB 
16 881 bp Resistant 160 XDR-TB 
17 881 bp Resistant 165 XDR-TB 
18 881 bp Resistant 182 XDR-TB 
19 881 bp Resistant (MIC >900) 218 XDR-TB 
20 881 bp Resistant (MIC >900) 152 XDR-TB 
21 2181 bp Resistant (MIC >900) 146 XDR-TB 
22 299 bp Resistant (MIC >900) 199 MDR-TB 
23 299 bp Resistant (MIC >900) 234 MDR-TB 




Supplemental Table 3. MUT pncA clinical M. tuberculosis isolates.  
Sample pncA SNP Phenotypic PZA 
DST 




1 Cys14Arg Resistant 148 MDR-TB 
2 Leu120Pro Resistant 154 XDR-TB 
3 Ile131Ser Resistant 150 XDR-TB 
4 Gly102Val Resistant 143 XDR-TB 
5 INS: Codon 173 (G) Resistant 163 XDR-TB 
6 
INS: Codon 12 (G) 
Resistant 147 XDR-TB 
7 
Val139Ala 
Resistant 146 XDR-TB 
8 
Tyr103STOP 
Resistant 135 XDR-TB 
9 
Asn118Ser 
Resistant 152 MDR-TB 
10 
Glyc97Asp 
Resistant 97 XDR-TB 
11 
Ala134Val 
Resistant 131 XDR-TB 
12 
Ser59Pro 
Resistant 122 XDR-TB 
13 His71Tyr Resistant 127 XDR-TB 
14 
Ser179Arg 
Resistant 97 MDR-TB 
15 
Ser185Thr 
Resistant 179 XDR-TB 
16 
Val9Leu 
Resistant 149 XDR-TB 
17 
Ala146Thr 
Resistant 190 XDR-TB 
18 
Tyr103His 
Resistant 158 XDR-TB 
19 
Ser164Pro 
Resistant 149 XDR-TB 
20 
Met1Thr 
Resistant 151 XDR-TB 
21 
Gly132Ala 
Resistant 143 XDR-TB 
22 
Gly97Asp 
Resistant 146 XDR-TB 
23 
Asp8Asn 
Resistant 130 XDR-TB 




Supplemental Table 4. WT pncA clinical M. tuberculosis isolates. 
Sample pncA SNP Phenotypic PZA 
DST 




1 Wild type Susceptible 132 XDR-TB 
2 Wild type Susceptible 145 XDR-TB 
3 Wild type Susceptible 128 XDR-TB 
4 Wild type Susceptible 135 MDR-TB 
5 Wild type Susceptible 107 MDR-TB 
6 Wild type Susceptible 125 XDR-TB 
7 Wild type Susceptible 119 MDR-TB 
8 Wild type Susceptible 112 MDR-TB 
9 Wild type Susceptible 122 MDR-TB 
10 Wild type Susceptible 127 XDR-TB 
11 Wild type Susceptible 97 MDR-TB 
12 Wild type Susceptible 104 XDR-TB 
13 Wild type Susceptible 118 XDR-TB 
14 Wild type Susceptible 100 MDR-TB 
15 Wild type Susceptible 103 XDR-TB 
16 Wild type Susceptible 153 XDR-TB 
17 Wild type Susceptible 114 XDR-TB 
18 Wild type Susceptible 104 MDR-TB 
19 Wild type Susceptible 130 XDR-TB 
20 Wild type Susceptible 121 XDR-TB 
21 Wild type Susceptible 122 XDR-TB 
22 Wild type Susceptible 136 MDR-TB 
23 Wild type Susceptible 134 XDR-TB 
 






Virtual sequencing of the entire pncA gene target in a single tube using LATE-PCR and Lights-
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The anti-TB drug pyrazinamide (PZA) is an integral component of the standardized TB treatment 
regimen recommended by the WHO. The continued inclusion of PZA in novel anti-TB treatment 
regimens is also largely due to its unique synergistic properties with new TB drugs, namely 
Protomanid and Bedaquiline.  Unfortunately, drug susceptible testing (DST) for PZA is rarely 
performed, due to associated limitations inherent to DST. This is a major problem because growing 
evidence supports the fact that a great many mutations in the pncA gene confer resistance to PZA and 
that only a wild type pncA genotype correlates with PZA susceptibility. A rapid high resolution 
method for analysing the sequence of the pncA gene is therefore urgently needed. 
 
Methods 
LATE-PCR based technique in combination with fluorescence probes to identify mutations along the 
entire length of the pncA gene. Following amplification, the temperature of the reaction is lowered to 
allow the 34 Lights-On/Lights-Off fluorescent probes to cover the single-stranded DNA templates. A 
fluorescent signature reveals the presence/absence of mutations, which are all distinguished from a 
highly reproducible wild-type fluorescent signature.  
 
Results 
The assay has been tested against 414 purified DNA isolates. These isolates comprise 184 (44.4%) 
pncA wild type and 230 (55.6%) pncA mutant strains. Among these isolates 179 (98.4%) were 
correctly genotyped as pncA wild type and 229 (98.7%) were correctly genotyped as pncA mutant. 3 
wild type isolates were incorrectly called as mutant and 3 isolates with mutations were incorrectly 
called as wild type. This results in a sensitivity of 98.7% (95% CI: 97.3 – 100) and specificity of 









We have successfully designed and tested a single closed-tube assay that is able to identify and 
distinguish the wild type pncA gene from strains with any genetic alterations and provides an accurate 
and rapid method to predict a PZA susceptible strain. Additional refinements will improve 
identification of the rare synonymous mutations and the few non-synonymous mutations in pncA that 
were not correctly scored as PZA resistance.  This virtual sequencing method is a promising advance 
in novel diagnostics for PZA. 





Mycobacterium tuberculosis is a pathogen which causes tuberculosis (TB), an airborne infectious 
disease which is curable if diagnosed and treated. The current burden of TB on the health authorities 
can in part be attributed to drug resistance (DR). It is important to control and reduce the rates of DR-
TB as it places a huge financial and public health burden on national TB control programmes across 
the globe (1). 
The anti-TB drug pyrazinamide (PZA) is an integral component of the standardized TB treatment 
regimen for drug susceptible and drug resistant TB recommended by the WHO (2, 3). PZA will 
remain an important anti-TB drug in the future due to inclusion in the latest WHO update on MDR-
TB treatment guidelines (3). The continued inclusion of PZA in novel anti-TB treatment regimens is 
also largely due to its unique synergistic properties with new TB drugs, namely Protomanid and 
Bedaquiline (4, 5). It is thus important to be able to detect resistance to PZA so that the patient’s 
treatment is not compromised. Unfortunately, drug susceptibility testing (DST) for PZA is rarely 
performed, due to pH and inoculum size limitations inherent to DST (6-8). For this reason, the WHO 
has not approved a standardized culture-based method for PZA DST due to the complexity and 
inconsistency of the currently available culture-based tests (2, 9-11).   
This has led to many researchers investigating the genotypic relationship to phenotypic PZA 
resistance. Numerous studies have demonstrated that mutations in pncA are the primary mechanism of 
resistance to PZA (12-14). It is hypothesized that mutations in the pncA gene substantially decreases 
PZase activity, thereby limiting the conversion of PZA to the active form of pyrazinoic acid (POA) in 
M. tuberculosis (15). Extensive DNA sequencing studies of the pncA gene have revealed that 
mutations and/or polymorphisms occur across the entire length of the gene, making it a complex 
target for the development of a genetic-based DST to identify resistance causing mutations (16-19). A 
recent systematic review identified over 600 mutations in the pncA gene (20). This implies that 
sequencing the entire pncA gene is essential in order to capture all the possible mutations and to 
differentiate between those that cause and those that do not cause. Recent studies have also suggested 
that PZA resistance may be conferred via an alternative mechanism(s), namely the rspA and panD 




genes (21, 22). However, due to the lack of convincing evidence of their involvement in PZA 
resistance, pncA remains the primary gene conferring resistance (23, 24). 
Culture-based phenotypic DST is time consuming and requires specialized laboratories and laboratory 
equipment. Sanger DNA sequencing of pncA is attractive alternative DST (8, 12-14). While Sanger 
sequencing significantly improves time to identifying resistance, a rapid point of care diagnostic 
similar to GeneXpert MTB/RIF (Cepheid, Sunnyvale, CA) would be the ideal solution (25). The most 
commonly used genetic method to identify changes in the pncA gene is standard polymerase chain 
reaction (PCR) of the target region (pncA) and subsequent Sanger sequencing of the amplicon. Other, 
more expensive genetic methods include deep sequencing and whole genome sequencing (26).  
Linear-after-the-exponential (LATE)-PCR is a form of non-symmetric PCR that efficiently generates 
single-stranded DNA by use of a combination of a Limiting Primer (
L
) and Excess Primer (
X
) with 





[0] ≥0. The initial amplification step involves exponential amplification. However, when the 
Limiting Primer runs out the kinetics switch to linear amplification of the Excess Primer strand only. 
Thus, LATE-PCR generates a large number of single strands of the target gene. This study makes use 
of LATE-PCR coupled with Lights-On/Lights-Off probes to identify changes in a desired target 
region (27-29) and to relate these finding to Sanger sequencing results as well as culture-based 
phenotypic susceptibility data. 
 
Methods 
Clinical isolate selection 
A convenience sample set of 414 clinical M. tuberculosis isolates (both PZA susceptible and PZA 
resistance genotypes) were selected for testing the diagnostic utility of LATE-PCR in combination 
with Lights-On/Lights-Off probes for the detection of pncA mutations conferring PZA resistance. 
These samples were selected from a culture bank of isolates collected from patient’s resident in four 
provinces in South Africa; Free State; Eastern Cape; Gauteng and the Western Cape. This study was 
approved by the Health Ethics Research Committee of Stellenbosch University (Ethics number: 
N12/01/001). 





DNA was purified from each isolate as per the procedure as described by Warren et al (30). Briefly, 
each clinical isolate of M. tuberculosis was inoculated under biosafety level 3 conditions onto solid 
7H10 media and incubated at 37°C for 4-6 weeks. The plates were then transferred to an oven at 80°C 
for 1 hour to ensure heat killing of mycobacteria. 30 ml of extraction buffer (5% sodium glutamate, 50 
mM Tris-HCl [pH 7.4], and 25 mM EDTA) was added to each plate in a biosafety class 2 laminar 
flow hood, and the colonies were gently scraped from the solid medium with a disposable loop. The 
liquid suspension from the plates was then transferred to a sterile 50 ml polypropylene tube containing 
approximately 20 glass beads (diameter, 4 mm) and vigorously vortexed to disrupt all colonies. 
Lysozyme (25 mg; Roche, Germany) and RNase A (50 g; Roche, Germany) were added, and the 
suspension was incubated after gentle mixing for 2 hours at 37°C. Thereafter, 600 µl of 10x 
proteinase K buffer (5% sodium dodecyl sulfate, 100 mM Tris-HCl [pH 7.8], 50 mM EDTA) and 1.5 
mg of proteinase K (Roche, Germany) were added and the suspension was incubated at 45°C for 16 
hours. An equal volume of phenol-chloroform-isoamyl alcohol (25/24/1) was then added and 
intermittently mixed over a period of 2 hours at room temperature. Following centrifugation at 3,000 
x g for 20 minutes, the resultant aqueous phase was re-extracted with an equal volume of chloroform- 
isoamyl alcohol (24/1) and centrifuged as described above. The resultant DNA was then precipitated 
with the addition of 3 M sodium acetate (pH 5.2) (600 µl) and an equal volume of isopropanol and 
immediately collected on a fine glass rod. The DNA was washed in 70% ethanol and allowed to air 
dry at room temperature. The purified DNA was re-dissolved in 300 µl TE (10 mM Tris-HCl [pH 8.0], 
1 mM EDTA). 
 
Genotypic characterisation 
The pncA gene was Sanger sequenced for all samples according to the method of Streicher et al (25). 
Briefly the pncA gene was amplified using the primers shown in Table 1. These primers were 
designed to amplify a product of 738 bp that includes the full length of the pncA gene (561 bp), as 
well as 80 bp of the upstream sequence and 97 bp of the downstream sequence. Each reaction mixture 
(25 μl) contained 1 to 2.5 μl of template DNA (purified DNA), 0.75 μM each PCR primer, 1× buffer, 




0.8 mM deoxynucleoside triphosphates, 0.125 μl (0.625 U) of HotStarTaq polymerase (Qiagen, 
Germany), and 2 μM Syto9 green-fluorescent nucleic acid stain (Invitrogen, CA, USA). The 
amplification protocol consisted of an initial activation step of 95°C for 15 minutes, followed by 50 
cycles of 94°C for 30 seconds, 60°C for 30 seconds, and 72°C for 1 minute and a final elongation step 
of 10 minutes at 72°C. Water was included as a negative control, while H37Rv DNA was included as 
a positive control. Amplification was confirmed by the detection of a distinct fluorescent melting 
curve signature consisting of two maxima (±92°C and ±93.5°C, respectively) by high-resolution 
melting analysis. Post-PCR clean-up was done with the Agencourt AMPure XP PCR1 purification 
system (Agencourt Bioscience Corporation, Beckman Coulter, Beverly, MA). PCR products were 
sequenced in both directions with the JpncAs Forward and JpncAs Reverse primers (Table 1). The 
DNA sequencing reaction was done on a GeneAmp 9700 thermal cycler (Applied Biosystems, Foster 
City, CA, USA) with the following program: 5 minutes at 94°C, followed by 25 cycles of 94°C for 10 
seconds, 55°C for 10 seconds, and 60°C for 4 minutes, using the BigDye Terminator v3.1 Cycle 
Sequencing kit (Applied Biosystems, Austin, TX, USA). The products were then electrophoresed on 
an ABI3730xl genetic analyzer (Applied Biosystems, Foster City, CA, USA). Sequences were 
analysed on the BioEdit sequence alignment editor (http://www.mbio.ncsu.edu/bioedit/bioedit.html) 
with H37Rv as the reference strain. 
 
LATE-PCR  
LATE-PCR primers (Table 1) were designed to amplify a 685 bp amplicon encompassing the entire 
coding region of the pncA gene, including 37 bp of the upstream sequence and 24 bp of the 
downstream sequence. Lights-On/lights-Off probes were designed to cover the amplicon, according to 
Rice et al protocol (28). Briefly, probes of between 20-26 bp were designed to complement the single 
stranded DNA generated by the LATE-PCR of the selected target, pncA. Each Lights-On probe is 
labelled with a fluorophore, a molecular beacon with a two base pair self-complementary stem. A 
Lights-Off probe is labelled with only a quencher moiety, such as a black hole quencher. Each Lights-
Off probe serves to absorb energy from the fluorophore of its adjacent Lights-On probe, when both 
are bound to a target. As the signal from each Lights-On probe is extinguished, multiple pairs of 




probes of the same colour or different colours can be used to analyse sequences several hundred 
nucleotides long. These probes are grouped into different fluorophore colours as well as a temperature 
range from high to low (Figure 1). Some probes included nucleotide mismatches to their target 
sequences to adjust the probe melting temperature. The probe Tm and binding were checked on 
Visual-OMP software (DNA Software Inc., Ann Arbor, MI, USA). Each fluorescent contour was 
transformed into its first derivative curve, which we refer to as a fluorescent signature. 
Each reaction mixture (25 μl) contained 1 to 2.5 μl of template DNA (purified DNA), 10 μM of the 
pncA_LP3 and 100 μM of the pncA_XP3 PCR primers (Table 1), 10× PCR buffer, 50 mM 
magnesium, 10 μM of prime safe, 10 mM deoxynucleoside triphosphates, 10 μM of each of the ON 
probes and 200 μM of each of the OFF probes and 0.125 μl (1.5 U) of Taq polymerase (Invitrogen, 
United States of America). All reagents were added in a PCR preparation room, free of any DNA 
contamination. The reagent mix was then taken to another clean room where the DNA for each 
sample was added under sterile conditions and the tube sealed. This was done in order to prevent any 
cross contamination of the sample and to minimize the risk of PCR contamination. Water was 
included as a negative control, while H37Rv DNA was included as a positive control. The 
amplification protocol consisted of 60 cycles of 97°C for 7 seconds, followed by 77°C for 1 minute; 
this was followed by a final elongation step of 75°C for 10 minutes. Following amplification 
(generation of single stranded DNA), the temperature of the reaction was lowered to 25
o
C for 10 
minutes. This results in the coating of the single-stranded DNA templates with 34 Lights-On/Lights-





a step wise gradient, 1°C for 30 seconds to allow the machine to measure the fluorescence; the probes 
are melted off of the target and the resulting fluorescent signature. Each fluorescent signature was 
compared to the signature of a pan-susceptible strain (H37Rv). Deviations in the signature pattern 
were interpreted to reflect the presence mutations in the pncA gene as they would alter the melting 
temperature of the complementary probe.  
If any discordance between the LATE-PCR and Sanger sequencing results were observed, the LATE-
PCR was repeated and the single stranded products were subsequently Sanger sequenced using the 
GeneAmp 9700 thermal cycler (Applied Biosystems, Foster City, CA, USA) as described above.  





The sensitivity and specificity of the DNA sequencing method were determined with Statistica 7.1. 
 
Table 1. Primers for amplification of the pncA gene.  
JpncAs Forward 5′ – GGCGTCATGGACCCTATA – 3′ 
JpncAs Reverse 5′ – GTGAACAACCCGACCCAG – 3′ 
pncA_LP3 5’ – GCGGCGTCATGGACCCTATATCTGTGGCTGCCGCGTC – ‘3 
pncA_XP3 5’ – TTGCTCCACCGCCGCCAACAGTTCAT – ‘3 
 
Results 
The 34 fluorescent probes were successfully designed for the cover the entire pncA gene including 
upstream and downstream flanking regions (Table 2). These probes were be grouped into three groups 
according to their fluorophore labels (Quasar, Cal Red and Cal Orange) (Figure 1), Each ON probe 
was linked to an adjacent OFF probe (Figure 1). This design together with each probe having a 
specific Tm creates a distinct melt signature which is used to determine the presence or absence of a 
nucleotide change in the pncA gene and flanking regions.  
Figure 1. pncA probes in the three fluorescence colours showing each probes respective Tm. 
 
 




Table 2. List of the pncA probes showing the fluorescence colour, Tm and probe sequence. 
Fluorophore 
Colour Probe name 
Probe 
Tm (C) Probe Sequence 
Quasar670 pncA_probe_196_215_ON 74,5 5′ – AACGCCGCGCTGGAGGAGATGCTT – 3′ 
Quasar670 pncA_probe_216_230_OFF 60,6 5′ – GGCCGATACCACCGT – 3′ 
Quasar670 pncA_probe_406_425_ON 68,7 5′ – ACCATCGGAGCGTACAGCGGCTGT – 3′ 
Quasar670 pncA_probe_426_440_OFF 53,8 5′ – CTACAAGGGTGCCTA – 3′ 
Quasar670 pncA_probe_161_180_ON 64,7 5′ – ACAGTTGGTTTGCAGCTCCTGAGT – 3′ 
Quasar670 pncA_probe_181_195_OFF 55,2 5′ – GCACTGCCGGCGTCG – 3′ 
Quasar670 pncA_probe_546_565_ON_bovis 63,4 5′ – AAGACCCGGGTGATCACTTCTCTT – 3′ 
Quasar670 pncA_probe_566_580_OFF 51,3 5′ – AAGGACTTCCACATC – 3′ 
Quasar670 pncA_probe_616_635_ON 58,1 5′ – AACGCTATCAGTGACTACCTGGTT – 3′ 
Quasar670 pncA_probe_636_650_OFF 51,1 5′ – CGCTGCGTTGGCTCG – 3′ 
Quasar670 pncA_probe_441_460_ON 54,5 5′ – AATCGGCAATTGAGTCGGTGTTTT – 3′ 
Quasar670 pncA_probe_461_475_OFF 47,3 5′ – CAGTCTGGACGCG – 3′ 
Cal Red610 pncA_probe_511_530_ON 69,0 5′ – ACTTCCTCGTCGTGGCCATCGCGT – 3′ 
Cal Red610 pncA_probe_531_345_OFF_bovis 53,4 5′ – CGGCACACTGGACTA – 3′ 
Cal Red610 pncA_probe_651_670_ON 67,8 5′ – AATCGCTGGCGGTAACTGGTGGTT – 3′ 
Cal Red610 pncA_probe_671_685_OFF 60,4 5′ – TTCTGCGAGGGTGGC – 3′ 
Cal Red610 pncA_probe_301_320_ON 64,4 5′ – AACATCGATCATTGTGTGCGCCTT – 3′ 
Cal Red610 pncA_probe_321_335_OFF 54,2 5′ – TGTGGTCGGTATTGC – 3′ 
Cal Red610 pncA_probe_336_355_ON 62,2 5′ – AGCGTGGCGTCGATGAGGTTGACT – 3′ 
Cal Red610 pncA_probe_356_370_OFF 48,0 5′ – AGTTGGCTGTGGCAA – 3′ 
Cal Red610 pncA_probe_231_250_ON 62,8 5′ – AAGACCTGACAGTGGGTGTGTCTT – 3′ 
Cal Red610 pncA_probe_251_265_OFF 43,9 5′ – ATCAGGGTGTTGGTG – 3′ 
Cal Red610 pncA_probe_721_740_ON 54,0 5′ – TTCCGAACTTATGGTGGACGTAAA – 3′ 
Cal Red610 pncA_probe_741_755_OFF 46,3 5′ – TTGCTTGGGCAGTTGC – 3′ 




Cal Orange560 pncA_probe_266_285_ON 73,4 5′ – TGGCGGTACGCAATGGCTTGGCCCA – 3′ 
Cal Orange560 pncA_probe_286_300_OFF 60,1 5′ – AGACGGCCGAGGAC – 3′ 
Cal Orange560 pncA_probe_581_600_ON 68,6 5′ – ACACCATCACGTCGTGGCAACCGT – 3′ 
Cal Orange560 pncA_probe_601_615_OFF 56,8 5′ – CCGAGGCGGCGGGCT – 3′ 
Cal Orange560 pncA_probe_476_495_ON 60,3 5′ – ACCTCTCGGCGTGGACTTCTATCCGT – 3′ 
Cal Orange560 pncA_probe_496_510_OFF 48,3 5′ – ATTGCGTTAGCGGTA – 3′ 
Cal Orange560 pncA_probe_686_705_ON 57,4 5′ – TTTCGTTGACGTGCAGAATGACAA – 3′ 
Cal Orange560 pncA_probe_706_720_OFF 46,7 5′ – TGCGGGTGTTGGTCA – 3′ 
Cal Orange560 pncA_probe_371_390_ON 53,2 5′ – AAAGAATGGTACGTCACTGCTGTT – 3′ 
Cal Orange560 pncA_probe_391_405_OFF 42,0 5′ – TCGGAGGAGTTGACG – 3′ 
 
To determine the diagnostic utility of the LATE-PCR assay, DNA from 414 phenotypically PZA 
susceptible and resistant M. tuberculosis isolates were amplified and sequenced. The Sanger 
sequencing method identified 184 (44.4%) isolates with a wild type pncA sequence and 230 (55.6%) 
isolates with a mutant pncA sequence. In total 76 different pncA mutations were identified, including 
insertions (n = 9), deletions (n = 5), single nucleotide polymorphisms (SNPs) (n = 54; 1 synonymous 
and 53 non-synonymous) as well as double SNPs (n = 8).  
Table 3 shows the complete list detailing samples with their associated pncA genotype as well as 
whether a change in the LATE-PCR fluorescence signature was observed. Examples of fluorescence 
signatures for wild type and mutant isolates are shown in Figures 2-10. 
Concordance between the LATE-PCR and Sanger sequencing results were observed in 406 (98.1%) 
isolates. LATE PCR and Sanger sequencing was repeated on the remaining 8 isolates. Two isolates 
which were originally found to be pncA wild type and had a change in the LATE-PCR melt curve, 
were upon repeating testing found to have a mutation in pncA. The remaining 3 isolates were found to 
have a shift in the LATE-PCR melt curve but were still wild type for pncA and 3 were found to not 
have a shift in the LATE-PCR melt curve but a nucleotide change in the pncA gene was again 
observed. This results in 179 of 182 wild-type isolates (98.4%) were correctly genotyped as pncA wild 




type and 229 of 232 (98.7%) were correctly genotyped as pncA mutant. This implies a sensitivity of 
98.7% (95% CI: 97.3 – 100) and specificity of 98.4% (95% CI: 96.5 – 100) assuming that the 
sequencing is correct and no heterogeneity was missed.  
 
Discussion 
The inclusion of PZA in the latest WHO MDR-TB treatment guidelines indicates that PZA will 
continue to play an important role in the treatment of drug susceptible (DS) and drug resistant (DR) 
TB. The lack of standardized routine PZA DST due to technical challenges means that a molecular-
based diagnostic that investigates the pncA gene would provide the most insight into determining PZA 
susceptibility. 
This study made use of non-symmetrical PCR method, which generates a large amount of single-
stranded DNA of a specific target region. Fluorescent probes were designed to cover the single 
stranded DNA of the specific target region. These probes, which are separated by fluorescent colours 
and Tms, are melted off the single stranded DNA to produce a melt signature. The presence of a 
mutation in the specific target region should result in a shift in the Tm that the probe melts off and 
causes a shift in the melt signature.  
This technique was successfully applied to the pncA gene and tested on a large cohort of purified 
DNA clinical isolates from South Africa. Examples of the generated melt signatures are given in the 
Figures 2 – 10. Each sample has signatures for the three different fluorescent colours namely; 
Quasar670; Cal Red610 and Cal Orange560. The changes in the melt signatures are indicated by 
black arrows. This method achieved excellent results, with a final sensitivity of 98.7% (95% CI: 97.3 
– 100) and specificity of 98.4% (95% CI: 96.5 – 100). The test utility was not compromised by the 
position in the gene that was analysed. There was a good distribution of pncA SNPs across the entire 
pncA gene as shown in Figure 11, which is a good representation of the distribution of mutations 
observed globally (20). 
Of the 6 isolates which showed discordant results, 3 were pncA wild type using Sanger sequencing but 
showed a shift in the LATE-PCR melt signature and 3 were pncA mutant using Sanger sequencing but 
showed no shift in the LATE-PCR melt signature. The 3 pncA wild type (as determined by Sanger 




sequencing) isolates all had changes in the Cal Red fluorophore, however the melt signature shift may 
be due an underlying population that has a mutation in the pncA gene but we are unable to detect on 
the Sanger sequencing. This could be resolved using deep sequencing to identify this underlying 
population. The 3 pncA mutant isolates do not cluster together (codon 14, codon 152 and codon 187). 
In isolate R5526 the mutation at codon 187 (stop codon) was not detected because this mutation fall at 
the end of the probe thereby not influencing the Tm sufficiently to be detected. The other two 
mutations both have other isolates with mutations in the same codon which were identified. The may 
indicate that the probe has not effectively bound to the target strand of DNA and thus not resulted in a 
melt signature shift.  
The excellent sensitivity and specificity coupled with a rapid turnaround time for a result (same day) 
means that LATE-PCR holds promise for a diagnostic to identify pncA mutations. LATE-PCR offers 
an attractive alternative to Sanger sequencing due to the rapid turnaround time in comparison to the 
Streicher et al manuscript (25). It also offers a much simpler alternative to whole genome sequencing 
(WGS) and next generation sequencing (NGS), as there is no need for expensive WGS/NGS 
sequencing equipment. However, we acknowledge some limitations. Firstly, the samples used in this 
study were purified DNA which requires culturing for 4-6 weeks as well as DNA extraction. Secondly, 
the full spectrum of mutations has not been evaluated. Thirdly, this technique needs to be validated 
using a more “raw” specimen type such as the Hain Lifescience Genolyse Kit for Genomic Bacterial 
DNA (Hain Lifescience, GmbH) from both sputum as well as culture.  
 
Conclusion  
We have successfully designed and tested a single closed-tube assay that is able to identify and 
distinguish the wild type pncA gene from strains with pncA genes containing genetic variants and 
thereby provides an accurate and rapid method to predict a PZA susceptible strain. Additional 
refinements will improve identification of the rare synonymous mutations and the few non-
synonymous mutations in pncA that were not correctly scored as PZA resistance. This virtual 
sequencing method is a promising advance in novel diagnostics for PZA. However, many more pncA 
mutations need to be evaluated to confirm that the assay works optimally. We also need to further the 




understanding of the mechanism of action to ensure that the assay is reliable enough to use in routine 
testing. This assay could be integrated alongside the GeneXpert or Line Probe Assay to determine the 
patient’s resistance profile so that the treatment can be optimised. 
Additional support: This study forms part of a bigger collaborative study, which includes an 
additional 240 M. tuberculosis strains from the United States of America (USA). The technique has 
been successfully replicated in multiple laboratories with similar successful as described in this study. 
The preliminary results of the isolates from the USA study show 217 of 240 (90.4%) samples 
correctly identified using the LATE-PCR with Lights-On/Lights-Off probes. There are 3 samples 
which are pncA wild type according to Sanger sequencing but called as having a pncA mutation, and 
there are 20 samples which are found to have pncA mutations according to Sanger sequencing but 
were called as pncA wild type. This results in a sensitivity of 98.2% (95% CI: 96.2 – 100) and a 
specificity of 72.6% (95% CI: 62.4 – 82.8).  
 
Additional note: The assay could be modified so that silent or SNPs not associated with resistance can 
be masked using an additional probe which would bind preferentially when the mutant is present (out 
competes the mutant probe) which would result in a wild type melt signature.  
 
Additional note: The correlation between Sanger sequencing and PZA DST should be noted. There 
was a total of 414 isolates. 50 isolates had no PZA DST data and were excluded for this calculation.  
The sensitivity was 98.4% (95% CI: 96.6 – 100) and specificity was 98.3% (95% CI: 96.4 – 100). 




















Figure 2. Quasar670 for sample FS 028 showing a wild type melt signature (Supp Table 1). 
Stellenbosch University  https://scholar.sun.ac.za





















Figure 3. Cal Red610 for sample FS 028 showing a wild type melt signature (Supp Table 1). 
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Figure 4. Cal Orange560 for sample FS 028 showing a shift in the melt signature, indicated by the black arrow (Supp Table 1).  
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Figure 5. Quasar670 for sample FS 029 showing a wild type melt signature (Supp Table 1). 
Stellenbosch University  https://scholar.sun.ac.za




















Figure 6. Cal Red610 for sample FS 029 showing a shift in the melt signature, indicated by the black arrow (Supp Table 1). 
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Figure 7. Cal Orange560 for sample FS 029 showing a wild type melt signature (Supp Table 1). 
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Figure 8. Quasar670 for sample FS 031 showing a wild type melt signature (Supp Table 1). 
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Figure 9. Cal Red610 for sample FS 031 showing a wild type melt signature (Supp Table 1). 
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Figure 10. Cal Orange560 for sample FS 031 showing a wild type melt signature (Supp Table 1). 
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Figure 11. The distribution of tested pncA mutations and the frequency of each mutation. The three red arrows indicate the three codons which showed a 
discordant result. 
Stellenbosch University  https://scholar.sun.ac.za
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Supplemental Table 1. Sanger sequencing results of pncA gene with the changes observed with the 
Lights-On/Lights-Off probes.  
Number Sample pncA mutation Lights-On/Lights-Off change Comment 
1 EC 010A INS: Codon 173, Position 1 (G) QSR change 
 
2 EC 011.1 INS: Codon 173, Position 1 (G) QSR change 
 
3 EC 011.2 INS: Codon 173, Position 1 (G) QSR change 
 
4 EC 012A Wild type None 
 
5 EC 012B Wild type None 
 
6 EC 015 INS: Codon 173, Position 1 (G) QSR change 
 
7 EC 016 INS: Codon 173, Position 1 (G) QSR change 
 
8 EC 017 INS: Codon 173, Position 1 (G) QSR change 
 
9 EC 018 Wild type None 
 
10 EC 020 INS: Codon 173, Position 1 (G) QSR change 
 
11 EC 021 INS: Codon 173, Position 1 (G) QSR change 
 
12 EC 022 Gly102Val QSR change 
 
13 EC 023 INS: Codon 173, Position 1 (G) QSR change 
 
14 EC 024 Wild type None 
 
15 EC 025 INS: Codon 173, Position 1 (G) QSR change 
 
16 EC 026 INS: Codon 173, Position 1 (G) QSR change 
 
17 EC 029 Wild type None 
 
18 EC 031 Thr100Pro and STOP187Trp QSR change 
 
19 EC 031A Cys14Arg CR, CO change 
 
20 EC 035 Leu120Pro CR change 
 
21 EC 039 INS: Codon 173, Position 1 (G) QSR change 
 
22 EC 040 Ile131Ser CO change 
 
23 EC 041 Thr100Pro and STOP187Trp CR change 
 
24 EC 042 INS: Codon 173, Position 1 (G) QSR change 
 
25 EC 043 Cys14Arg QSR, CR, CO change 
 
26 EC 045 Wild type None 
 
27 EC 046 INS: Codon 173, Position 1 (G) QSR change 
 
28 EC 048 Wild type None 
 
29 EC 048A Wild type None 
 
30 EC 049 INS: Codon 173, Position 1 (G) QSR change 
 
31 EC 050 Cys14Arg CR change 
 
32 EC 051 Thr135Pro CR change 
 
33 EC 051B Thr135Pro CR change 
 





34 EC 052 INS: Codon 173, Position 1 (G) QSR change 
 
35 EC 053 Wild type None 
 
36 EC 054 Wild type None 
 
37 EC 055 Wild type None 
 
38 EC 056 INS: Codon 173, Position 1 (G) QSR change 
 
39 EC 057 INS: Codon 173, Position 1 (G) QSR change 
 
40 EC 058 Cys14Arg QSR change 
 
41 EC 059 Thr100Pro and STOP187Trp CR change 
 
42 EC 061 Tyr103His QSR change 
 
43 EC 062 INS: Codon 173, Position 1 (G) QSR change 
 
44 EC 063 INS: Codon 173, Position 1 (G) QSR change 
 
45 EC 065 Wild type None 
 
46 EC 066 Wild type None 
 
47 EC 067 Thr135Pro CR change 
 
48 EC 068 Wild type None 
 
49 EC 069 INS: Codon 173, Position 1 (G) QSR change 
 
50 EC 070 INS: Codon 173, Position 1 (G) QSR change 
 
51 EC 071 Wild type None 
 
52 EC 072 INS: Codon 173, Position 1 (G) QSR change 
 
53 EC 072B INS: Codon 173, Position 1 (G) QSR change 
 
54 EC 073 Wild type None 
 
55 EC 074 INS: Codon 173, Position 1 (G) QSR change 
 
56 EC 075 INS: Codon 173, Position 1 (G) QSR change 
 
57 EC 076 Gly108Arg CO change 
 
58 EC 077 INS: Codon 173, Position 1 (G) QSR change 
 
59 EC 080 Wild type None 
 
60 EC 081 INS: Codon 173, Position 1 (G) QSR change 
 
61 EC081A INS: Codon 173, Position 1 (G) QSR change 
 
62 EC 082 Wild type None 
 
63 EC 083 Wild type None 
 
64 EC 084 INS: Codon 173, Position 1 (G) QSR change 
 
65 EC 085 Wild type None 
 
66 EC 086 Ser65Ser CR change 
 
67 EC 087 Wild type CR change 
 
68 EC 088 Wild type None 
 
69 EC 090 Wild type None 
 





70 EC 091 INS: Codon 173, Position 1 (G) QSR change 
 
71 EC 092 Cys72Gly CR change 
 
72 EC 093 INS: Codon 173, Position 1 (G) QSR change 
 
73 EC 095 Wild type None 
 
74 EC 096 INS: Codon 173, Position 1 (G) QSR change 
 
75 EC 097 INS: Codon 173, Position 1 (G) QSR change 
 
76 EC 098 Cys14Arg CR, CO change 
 
77 EC 098A Cys14Arg CR, CO change 
 
78 EC 099 INS: Codon 173, Position 1 (G) QSR change 
 
79 EC 100 INS: Codon 173, Position 1 (G) QSR change 
 
80 EC 104 Wild type None 
 
81 EC 105 INS: Codon 173, Position 1 (G) QSR change 
 
82 EC 106 Wild type None 
 
83 EC 108 INS: Codon 173, Position 1 (G) QSR change 
 
84 EC 109 INS: Codon 173, Position 1 (G) QSR change 
 
85 EC 110 INS: Codon 173, Position 1 (G) QSR change 
 
86 EC 111 Glu10Pro CR, CO change 
 
87 EC 113A Leu182Ser CR change 
 
88 EC 114 Thr114Met QSR, CR, CO change 
 
89 EC 115 INS: Codon 173, Position 1 (G) QSR, CR change 
 
90 EC 116 Glyc97Asp QSR, CO change 
 
91 EC 303 Cys14Arg CR, CO change 
 
92 EC 304 Wild type None 
 
93 EC 305 Ala102Val QSR change 
 
94 EC 307A Wild type None 
 
95 EC 310 INS: Codon 173, Position 1 (G) QSR, CR change 
 
96 EC 311 Trp68Arg CR change 
 
97 EC 312 Wild type None 
 
98 EC 317 Val139Gly CO change 
 
99 EC 338B INS: Codon 173, Position 1 (G) QSR change 
 
100 EC 342 Wild type None 
 
101 EC 347 Wild type None 
 
102 EC 358 INS: Codon 173, Position 1 (G) QSR change 
 
103 EC 364 Wild type None 
 
104 EC 365 Tyr103His QSR, CO change 
 
105 EC 367 Ala98Val and Met175Val QSR, CO change 
 





106 EC 368B INS: Codon 173, Position 1 (G) QSR, CO change 
 
107 EC 372 Leu35Arg CO change 
 
108 EC 373 Wild type None 
 
109 EC 378 Leu35Arg CO change 
 
110 EC 379 INS: Codon 173, Position 1 (G) QSR change 
 
111 EC 379B INS: Codon 173, Position 1 (G) QSR change 
 
112 EC 382 Wild type None 
 
113 EC 382A Wild type None 
 
114 EC 383A Thr100Pro and STOP187Val CR change 
 
115 EC 385A INS: Codon 173, Position 1 (G) QSR change 
 
116 EC 385B INS: Codon 173, Position 1 (G) QSR change 
 
117 EC 386B INS: Codon 173, Position 1 (G) QSR change 
 
118 EC 387 Wild type None 
 
119 EC 503 Wild type None 
 
120 EC 504 Ser59Pro QSR, CR change 
 
121 EC 514 Ser104Arg CR change 
 
122 EC 525 Wild type None 
 
123 EC 525A Wild type None 
 
124 EC 531B Wild type None 
 
125 EC 536B Pro62Leu CO change 
 
126 EC 541A INS: Codon 173, Position 1 (G) QSR, CO change 
 
127 EC 548B Wild type None 
 
128 EC 549 INS: Codon 173, Position 1 (G) QSR, CO change 
 
129 EC 550 INS: Codon 173, Position 1 (G) QSR change 
 
130 EC 550A INS: Codon 173, Position 1 (G) QSR change 
 
131 EC 550B INS: Codon 173, Position 1 (G) QSR change 
 
132 EC 557 INS: Codon 173, Position 1 (G) QSR change 
 
133 EC 559 Wild type None 
 
134 EC 561 Ser65Ser CR change 
 
135 EC 565 Wild type None 
 
136 EC 565A Wild type None 
 
137 EC 567A Wild type None 
 
138 EC 569A Wild type None 
 
139 EC 569B Wild type None 
 
140 EC 573B INS: Codon 173, Position 1 (G) QSR change 
 
141 EC 577 Wild type None 
 





142 EC 578 INS: Codon 173, Position 1 (G) CR change 
 
143 EC 580 INS: Codon 173, Position 1 (G) QSR change 
 
144 EC 583 Ile31Ser CO change 
 
145 EC 589 Wild type None 
 
146 EC 589A Cys14Arg CR change 
 
147 EC 594A INS: Codon 173, Position 1 (G) QSR change 
 
148 EC 610 Wild type None 
 
149 FS 001 Thr135Pro CR change 
 
150 FS 002 Gly97Cys QSR change 
 
151 FS 003 Wild type None 
 
152 FS 004 Ser59Pro CR change 
 
153 FS 006 Arg154Gly CR change 
 
154 FS 007 Wild type None 
 
155 FS 007:2 Wild type CR change Discordant 
156 FS 008 Wild type None 
 
157 FS 009 Wild type None 
 
158 FS 010 Trp68Gly CR change 
 
159 FS 010:2 Trp68Gly CR change 
 
160 FS 011 Wild type None 
 
161 FS 011.2 Wild type None 
 
162 FS 012 Thr100Ile and Thr160Ala QSR + CR change 
 
163 FS 012:2 Thr100Ile and Thr160Ala QSR, CR change 
 
164 FS 012:5 Thr100Ile and Thr160Ala QSR, CR change 
 
165 FS 014 Thr100Ile and Thr160Ala QSR + CR change 
 
166 FS 015 Tyr103STOP QSR change 
 
167 FS 016 INS: Codon 12, Position 2 (G) CO change 
 
168 FS 017 Wild type None 
 
169 FS 018 INS: Codon 173, Position 1 (G) CR change 
 
170 FS 019 Wild type None 
 
171 FS 020 Wild type None 
 
172 FS 021 Ala134Val CR change 
 
173 FS 021A Ala134Val CR change 
 
174 FS 022 INS: Codon 131, Position 2 (GT) CR change 
 
175 FS 023 INS: Codon 12, Position 2 (G) QSR, CR, CO change 
 
176 FS 024 Wild type None 
 
177 FS 025 Wild type None 
 





178 FS 026 Wild type None 
 
179 FS 027 Wild type None 
 
180 FS 028 INS: Codon 12, Position 2 (G) CO change Fig 2-4 
181 FS 029 Val139Ala CR change Fig 5-7 
182 FS 031 Wild type None Fig 8-10 
183 FS 031:2 Asn118Ser QSR, CR, CO change 
 
184 FS 032 Wild type None 
 
185 FS 033 Wild type None 
 
186 FS 034 Ile31Asn CO change 
 
187 FS 035 Wild type None 
 
188 FS 036 Wild type None 
 
189 FS 036A Tyr103STOP QSR change 
 
190 FS 037 His51Pro CR change 
 
191 FS 038 Wild type CR change Discordant 
192 FS 038A Wild type None 
 
193 FS 039 Wild type None 
 
194 FS 040 Wild type None 
 
195 FS 041 Wild type None 
 
196 FS 042 Ser65Ser CR change 
 
197 FS 043 Wild type None 
 
198 FS 043A Wild type None 
 
199 FS 044 Gly132Ser CR change 
 
200 FS 045 Wild type None 
 
201 FS 046 INS: Codon 131, Position 1 (G) CR change 
 
202 FS 047 Wild type None 
 
203 FS 048 Wild type None 
 
204 FS 049A Wild type None 
 
205 FS 050 Wild type None 
 
206 FS 051 Ser65Ser CR change 
 
207 FS 052 Promotor region: -11, A>G CR change 
 
208 FS 053 Wild type None 
 
209 FS 054 Wild type None 
 
210 FS 055 Wild type None 
 
211 FS 056 Arg154Gly CR change 
 
212 FS 059 Wild type None 
 
213 FS 060 Wild type None 
 





214 FS 061 Wild type None 
 
215 FS 062 DEL: Codon 153, Position 3 (8bp) CR change 
 
216 FS 063 Glyc97Asp QSR change 
 
217 FS 064 Wild type None 
 
218 FS 065 Ser59Pro CR change 
 
219 FS 067 Wild type None 
 
220 FS 068 Wild type None 
 
221 FS 301 Wild type None 
 
222 FS 303 Wild type None 
 
223 FS 304 Leu35Arg CO change 
 
224 FS 305 DEL: Codon 130, Position 2 (T) QSR, CR change 
 
225 FS 306 Wild type None 
 
226 FS 308 Wild type None 
 
227 FS 309 Cys14Arg None Discordant 
228 FS 310 Wild type None 
 
229 FS 311 DEL: Codon 163, Position 3 (11bp) CR change 
 
230 FS 314 Wild type None 
 
231 FS 315 Wild type None 
 
232 FS 321 Wild type None 
 
233 FS 322 Wild type None 
 
234 FS 331 DEL: Codon 163, Position 3 (11bp) CR change 
 
235 FS 331B DEL: Codon 163, Position 3 (11bp) CR change 
 
236 FS 336 Promoter, -7: T>C CR change 
 
237 FS 338 Glyc97Asp QSR change 
 
238 FS 348 Thr135Pro CR change 
 
239 FS 351 Glyc97Asp QSR change 
 
240 FS 352 Wild type None 
 
241 FS 353 Wild type None 
 
242 FS 355 Wild type None 
 
243 FS 356 Thr135Pro CR change 
 
244 FS 358 INS: Codon 12, Position 2 (G) CO change 
 
245 FS 359 Ser65Ser CR change 
 
246 FS 500 Phe58Ser CR, CO change 
 
247 FS 501 Wild type None 
 
248 FS 503 Ser59Pro CR change 
 
249 FS 507 Wild type None 
 





250 FS 508 Wild type None 
 
251 FS 512 Wild type None 
 
252 FS 513 Arg154Gly CR change 
 
253 FS 519 Glyc97Asp QSR change 
 
254 FS 527 Wild type None 
 
255 FS 535 Wild type None 
 
256 FS 537 Wild type None 
 
257 FS 550 Wild type None 
 
258 FS 551 Wild type None 
 
259 FS 564 Wild type None 
 
260 FS 579 Wild type None 
 
261 FS 581 His51Pro CR change 
 
262 FS 582 Wild type None 
 
263 FS 583 Wild type None 
 
264 FS 583A Wild type None 
 
265 FS 584 Arg154Gly CR change 
 
266 FS 585 Glyc97Asp QSR change 
 
267 FS 588 Val73Ile CR change 
 
268 FS 588A Wild type None 
 
269 FS 591 Arg154Gly CR change 
 
270 FS 592 Wild type None 
 
271 FS 595A INS: Codon 173, Position 1 (G) QSR change 
 
272 FS 596 Wild type None 
 
273 FS 598 Wild type None 
 
274 FS 598A Wild type None 
 
275 GA 001 Wild type None 
 
276 GA 002 Wild type None 
 
277 GA 003 Wild type None 
 
278 GA 004 Wild type None 
 
279 GA 006A Wild type None 
 
280 GA 007 Wild type None 
 
281 GA 008 Arg154Gly QSR, CR change 
 
282 GA 009 INS: Codon 152, Position 3 (C) None Discordant 
283 GA 010 Glyc97Asp QSR, CO change 
 
284 GA 012 Wild type None 
 
285 GA 013A Wild type None 
 





286 GA 016 Wild type None 
 
287 GA 017 Val139Gly CR change 
 
288 GA 018 Val139Gly CR, CO change 
 
289 GA 020 Thr100Pro QSR change 
 
290 GA 022 Wild type None 
 
291 GA 024 Wild type None 
 
292 GA 027 Wild type None 
 
293 GA 029 INS: Codon 152, Position 3 (C) CR, CO change 
 
294 GA 029A INS: Codon 152, Position 3 (C) CO change 
 
295 GA 030 His71Tyr CR change 
 
296 GA 032 Wild type None 
 
297 GA 035 His71Tyr CR change 
 
298 GA 036 Wild type None 
 
299 GA 037 Wild type None 
 
300 GA 040 Wild type None 
 
301 GA 041 Glyc97Asp QSR change 
 
302 GA 042 Wild type None 
 
303 GA 043 Wild type None 
 
304 GA 044 Wild type None 
 
305 GA 045 INS: Codon 173, Position 1 (G) QSR, CR change 
 
306 GA 046 Wild type None 
 
307 GA 046A Wild type None 
 
308 GA 047 His71Tyr CR change 
 
309 GA 048 Wild type None 
 
310 GA 050 INS: Codon 173, Position 1 (G) QSR change 
 
311 GA 051 His71Tyr CR change 
 
312 GA 056 Wild type CR change Discordant 
313 GA 057 Wild type None 
 
314 GA 058 Wild type None 
 
315 GA 059 Wild type None 
 
316 GA 060 Wild type None 
 
317 GA 061 Wild type None 
 
318 GA 062 Wild type None 
 
319 GA 063 INS: Codon 152, Position 3 (C) CO change 
 
320 GA 064 Glyc97Cys QSR change 
 
321 GA 064A Gly97Cys QSR change 
 





322 GA 065 Wild type None 
 
323 GA 068 Wild type None 
 
324 GA 069 Wild type None 
 
325 GA 074 Cys14Arg CR, CO change 
 
326 GA 076 Wild type None 
 
327 GA 078 Wild type None 
 
328 GA 080 Wild type None 
 
329 GA 302 Ala134Asp QSR change 
 
330 GA 306 Wild type None 
 
331 GA 315 Wild type None 
 
332 GA 316 Wild type None 
 
333 GA 321 Wild type None 
 
334 GA 322 Tyr34Asp QSR, CR change 
 
335 GA 324 Ala102Val CR change 
 
336 GA 329 Wild type None 
 
337 GA 331 Cys14Arg CO change 
 
338 GA 342 Wild type None 
 
339 GA 346 Wild type None 
 
340 GA 359 DEL: Codon 130, Position 2 (T) CR change 
 
341 GA 360 Glyc97Asp QSR change 
 
342 GA 369 Wild type None 
 
343 GA 500 Wild type None 
 
344 GA 502 Wild type None 
 
345 GA 504 Wild type None 
 
346 GA 509 Wild type None 
 
347 GA 514 Wild type None 
 
348 GA 516 Wild type None 
 
349 GA 517 INS: Codon 173, Position 1 (G) QSR change 
 
350 GA 523 Wild type None 
 
351 GA 525 Ser66Pro CR, CO change 
 
352 GA 527A Ser65Ser CR change 
 
353 GA 531 Wild type None 
 
354 GA 532 Wild type None 
 
355 GA 535 Wild type None 
 
356 GA 536 INS: Codon 12, Position 2 (G) CO change 
 
357 GA 537 Wild type None 
 





358 GA 540 Wild type None 
 
359 GA 540A Wild type None 
 
360 GA 567A Ser65Ser QSR, CR change 
 
361 GA 567B Wild type None 
 
362 GA 569 Wild type None 
 
363 1093 Thr114Met CO change 
 
364 R 1 INS: Codon 131, Position 1 (GG) CR change 
 
365 R 32 Leu159Pro and Ser185Thr CR change 
 
366 R 40 INS: Codon 130, Position 1 (G) CR change 
 
367 R 44 Trp68Gly and Ser185Thr CR change 
 
368 R 65 Ser65Ser CR change 
 
369 R 77 Ser65Ser CR change 
 
370 R 103 Ser185Thr CR change 
 
371 R 166 DEL: Codon 58, Position 1 (T) and Ser179Arg QSR, CR change 
 
372 R 201 Wild type None 
 
373 R 224 Cys72Tyr QSR change 
 
374 R 238 Wild type None 
 
375 R 296 Wild type None 
 
376 R 309 DEL: Codon 58, Position 1 (T) QSR change 
 
377 R 350 Ser179Arg QSR change 
 
378 R 357 Ser185Thr CR change 
 
379 R 374 Val9Leu CR change 
 
380 R 394 Cys14Arg CR change 
 
381 R 455 His57Tyr and Ser185Thr CR change 
 
382 R 484 Tyr103His QSR change 
 
383 R 510 Tyr103STOP QSR change 
 
384 R 10 247 Wild type None 
 
385 R 1 142 DEL: Codon 153, Position 3 (8bp) CR change 
 
386 R 15 487 Wild type None 
 
387 R 2 654 Ala146Thr CO change 
 
388 R 2 757 Tyr103His CR change 
 
389 R 3 384 Ser164Pro QSR change 
 
390 R 3 989 Met1Thr CO change 
 
391 R 5 065 Gly132Ala CR change 
 
392 R 5 526 STOP187Tyr None Discordant 
393 R 9 339 Wild type None 
 





394 TT 8 Gly150Gly CR change 
 
395 TT 39 Tyr34STOP CR change 
 
396 TT 227 INS: Codon 152, Position 3 (G) QSR change 
 
397 TT 233 IIe31Ser CR change 
 
398 X 2 Cys14Arg CR change 
 
399 X 6 DEL: Codon 8, Position 1 (G) CO change 
 
400 X 9 INS: Codon 131, Position 1 (GG) CR change 
 
401 X 10 Thr100Ile and Thr160Ala QSR, CR change 
 
402 X 16 Val139Met CR change 
 
403 X 17 INS: Codon 97, Position 1 (GG) QSR change 
 
404 X 23 Val139Met CR change 
 
405 X 24 Gly105Asp QSR, CR change 
 
406 X 52 Tyr103His QSR change 
 
407 X 70 Gly97Asp QSR change 
 
408 X 74 Asp8Asn CO change 
 
409 X130 Thr100Ile and Thr160Ala QSR change 
 
410 X 136 Gly97Asp CO change 
 
411 X 138 Gln10Pro CO change 
 
412 X 160 Met1Thr CO change 
 
413 X 167 Ser164Pro QSR change 
 
414 X 199 INS: Codon 173, Position 1 (G) QSR change 
 
Abbreviations: QSR, Quasar; CR, Cal Red; CO, Cal Orange. 














Pyrazinamide (PZA) continues to form a vital component of the anti-TB treatment regimen. However, 
there is a significant lack of data regarding the actual incidence of PZA resistance, as noted in the 
WHO global report. The prevalence of PZA resistance by region as well as globally was largely 
unknown. This was due to the lack of reliable, standardized routine PZA DST. To address this 
knowledge gap we performed a systematic literature review and thereby estimated the rates of PZA 
resistance for each WHO region (Africa, Americas, Eastern Mediterranean, Europe, South East Asia, 
Western Pacific) as well as the pooled estimate for any TB; high-risk of MDR-TB and lastly MDR-
TB (1). Our findings showed a clear increase of PZA resistance in the groups (any TB; high-risk 
MDR-TB and MDR-TB) from 16.2% to 41.3% to 60.5% was observed. This was the first study to 
show the global estimates, and thereby presented novel and necessary data to inform on the 
prevalence of PZA resistance. The summary estimates of the MDR-TB group from the systematic 
review were found to be similar to those observed in a previous systematic review where they 
estimate PZA resistance prevalence to be at 51% (range 31% - 89%) (2). More recently a study 
observed an association between PZA resistance and MDR-TB in a multi-country surveillance project 
with comparable rates of PZA resistance (3). 
The importance of PZA in treatment has been recently reiterated by the WHO’s recommendation of a 
shortened MDR-TB regimen as well as clinical trials evaluating the efficacy of new regimens (4-6). 
This highlights the need for routine standardized PZA DST particularly in patients with MDR-TB 
where the strong association was observed with PZA resistance (1, 2). This is crucial when 
considering possible novel drug combinations (PaMZ) for the treatment of MDR-TB. Our systematic 
review (Chapter 2) highlighted the complexity of PZA resistance on a global scale in terms of 
genotypic identification of PZA resistance. To date more than 600 different mutations occurring at 
397 distinct positions in the pncA gene have been described (1, 7). The fact that there are so many 
different mutations means that understanding how each mutation is related to microbiological 
resistance is complex and still largely unknown. Furthermore, the clinical relevance of 
microbiological PZA resistance remains unknown with the exception of that patients with isolates 
with a raised PZA MIC have a poorer outcome. 






In chapter 3 we aimed to determine the prevalence of PZA resistance in a cohort of South African 
patients with a spectrum of different resistance phenotypes (pan-susceptible to XDR-TB). A 
significant increase of prevalence of PZA resistance from 0% (pan-susceptible) to 96% (XDR-TB) 
was shown. This clearly shows that the inclusion of PZA in the treatment regimen of most MDR- and 
XDR-TB cases is unlikely to provide therapeutic benefit. Our study makes a very strong case for 
routine PZA DST particularly in rifampicin resistant cases to confirm whether the inclusion of PZA in 
the treatment should be counted. Recently, targeted gene sequencing of the pncA gene has been 
suggested to be a rapid alternative to the technically challenging culture based DST method (8). In 
order to address this, our study investigated the correlation between phenotypic and genotypic data. 
The overall sensitivity was 95.0% (95% CI 92.1–98.0) and specificity was 99.1% (95% CI 98.4–
99.9), indicating that targeted pncA sequencing could be used to identify PZA resistance (9). The rates 
of predicting PZA resistance using pncA Sanger sequencing as described above relate well to previous 
studies, such as a recent study where they could predict between 85-90% of PZA resistance when 
using pncA. This is particularly significant as the study investigated around 5000 patients across 5 
different countries. This rate has been shown in previous studies across the globe (10-17). While no 
obvious association between strain lineage and PZA susceptibility. However the link between a strain 
lineage and a pncA mutation may be indicative of transmission.   
We propose that targeted pncA sequencing could be readily implemented into the routine diagnostic 
laboratory with a turnaround time of less than 48 hours from smear positive specimens (8). However, 
smear negative specimens would require prior MGIT culture which is in line with the current 
diagnostic guidelines for confirmation of rifampicin resistance using the MTBDRplus line probe 
assay.  
A significant knowledge gap existed in the literature as to which of the pncA mutations did not confer 
resistance at the standardized PZA concentration of 100 g/ml. This largely resulted from the poor 
reliability of the PZA DST. Chapter 4 describes 10 SNPs which were identified that were not involved 
in conferring resistance to PZA at 100 g/ml. These 10 SNPs include both non-synonymous and 





synonymous SNPs. However, this list may be larger than the 10 SNPs identified in this study and to 
address this, we collated a comprehensive list of all possible pncA mutations which have been 
reported not to confer resistance (18). Together this further highlights the need to decipher the role of 
each mutation in pncA in PZA resistance such that genetic tests can be accurately interpreted. 
Chapter 5 investigates the fitness cost of SNPs and large deletions located in the pncA gene. A 
significant difference in growth rate was observed. This crude measure of growth rate suggests a 
possible fitness cost to the organism. This fitness cost may translate to the diminished ability to 
transmit. However, preliminary data from the pncA large deletion isolates suggests that these changes 
in the gene do not prevent transmission. Understanding the impact of compensatory mutations 
associated with PZA resistance will be crucial for understanding how PZA resistant strains are 
transmitted. This differs from previous studies which have suggested that in vitro growth rate is a 
surrogate for fitness cost and the inability to transmit (19).  
Lastly, in Chapter 6 we developed (in collaboration with Brandeis University) and evaluated a novel 
rapid PZA diagnostic, using a combination of LATE-PCR technology and lights-on/lights-off probes. 
Fluorescent probes were successfully designed to cover the pncA gene and this assay was assessed 
covering over 50 different pncA mutations described using Sanger sequencing. The study produced an 
overall sensitivity of 98.7% (95% CI: 97.3 – 100) and specificity of 98.4% (95% CI: 96.5 – 100). This 
compares favourably with targeted pncA sequencing (8). We conclude that this technology could be 
used to rapidly identify patients with TB that are susceptible to PZA. However, we have noted certain 
limitations. In this study we used purified DNA which excludes the presence of possible PCR 
inhibitors and contaminates that could influence the fluorescent signatures. Our method now needs to 
be validated with DNA extracted from clinical specimens. 
Overall this thesis presents together new knowledge of PZA resistance in M. tuberculosis. Several key 
knowledge gaps have been addressed, however many more questions remain, in particular the 
mechanism of resistance. Nonetheless, data presented here offers the potential to inform TB control 
programs and has added significant insight into the understanding of PZA resistance in M. 
tuberculosis.  
 






1. Investigate fitness cost of different mutations in pncA using more refined techniques, such as 
competition assays. This will provide better insight into the different effects of the different 
mutations.  
2. Create more in vitro pncA mutants to investigate downstream transcriptional and proteomic 
changes associated with pncA mutations/deletions.  
3. Investigation of isolates with intermediate or reduced PZA resistance (<100 µg/ml) to 
understand why this occurs as well as to have clinical outcomes data.  
4. To expand to the number of isolates tested using the LATE-PCR technique, so that more 
mutations in pncA can be investigated.  
5. The LATE-PCR technique needs to be validated on a “raw” specimen type to assess the 
diagnostic utility for possible implemented of routine DST.  
6. Investigation of upstream mutations associated with PZA resistance and the mechanism of 
action.  
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